{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "af3636dc-e4ae-4593-8d03-b0e2cfe5d1d8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "article_table has 195695 rows.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>pmid</th>\n",
       "      <th>paragraph_number</th>\n",
       "      <th>section_path</th>\n",
       "      <th>text</th>\n",
       "      <th>section_path_vector</th>\n",
       "      <th>text_vector</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>36321821</td>\n",
       "      <td>0</td>\n",
       "      <td>Title</td>\n",
       "      <td>Diagnostic accuracy of vaccine and vaccine exc...</td>\n",
       "      <td>[-0.07106374204158783, 0.06475027650594711, -0...</td>\n",
       "      <td>[0.0653635561466217, -0.0196632519364357, -0.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>36321821</td>\n",
       "      <td>1</td>\n",
       "      <td>Abstract</td>\n",
       "      <td>For persons with immediate allergic reactions ...</td>\n",
       "      <td>[-0.07030734419822693, 0.08017940074205399, 0....</td>\n",
       "      <td>[0.047091107815504074, -0.05435621738433838, -...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>36321821</td>\n",
       "      <td>2</td>\n",
       "      <td>INTRODUCTION</td>\n",
       "      <td>Over 12.2 billion COVID‐19 vaccine doses have ...</td>\n",
       "      <td>[-0.045066457241773605, 0.058423690497875214, ...</td>\n",
       "      <td>[0.037329141050577164, -0.08426067233085632, -...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>36321821</td>\n",
       "      <td>3</td>\n",
       "      <td>INTRODUCTION</td>\n",
       "      <td>In the face of uncertainty regarding new vacci...</td>\n",
       "      <td>[-0.045066457241773605, 0.058423690497875214, ...</td>\n",
       "      <td>[0.028730379417538643, -0.02857697196304798, -...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>36321821</td>\n",
       "      <td>4</td>\n",
       "      <td>INTRODUCTION</td>\n",
       "      <td>To better inform the evidence base regarding s...</td>\n",
       "      <td>[-0.045066457241773605, 0.058423690497875214, ...</td>\n",
       "      <td>[0.008769247680902481, -0.03468548506498337, -...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       pmid  paragraph_number  section_path  \\\n",
       "0  36321821                 0         Title   \n",
       "1  36321821                 1      Abstract   \n",
       "2  36321821                 2  INTRODUCTION   \n",
       "3  36321821                 3  INTRODUCTION   \n",
       "4  36321821                 4  INTRODUCTION   \n",
       "\n",
       "                                                text  \\\n",
       "0  Diagnostic accuracy of vaccine and vaccine exc...   \n",
       "1  For persons with immediate allergic reactions ...   \n",
       "2  Over 12.2 billion COVID‐19 vaccine doses have ...   \n",
       "3  In the face of uncertainty regarding new vacci...   \n",
       "4  To better inform the evidence base regarding s...   \n",
       "\n",
       "                                 section_path_vector  \\\n",
       "0  [-0.07106374204158783, 0.06475027650594711, -0...   \n",
       "1  [-0.07030734419822693, 0.08017940074205399, 0....   \n",
       "2  [-0.045066457241773605, 0.058423690497875214, ...   \n",
       "3  [-0.045066457241773605, 0.058423690497875214, ...   \n",
       "4  [-0.045066457241773605, 0.058423690497875214, ...   \n",
       "\n",
       "                                         text_vector  \n",
       "0  [0.0653635561466217, -0.0196632519364357, -0.0...  \n",
       "1  [0.047091107815504074, -0.05435621738433838, -...  \n",
       "2  [0.037329141050577164, -0.08426067233085632, -...  \n",
       "3  [0.028730379417538643, -0.02857697196304798, -...  \n",
       "4  [0.008769247680902481, -0.03468548506498337, -...  "
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import os\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from collections import Counter\n",
    "import regex\n",
    "from sklearn.linear_model import LogisticRegressionCV\n",
    "import pickle\n",
    "\n",
    "\n",
    "CSV_FILE =  \"D:/ml_data/pubmed/pmc_result_vaccine_allergy_1year.csv\" # \"example_data.csv\"\n",
    "PARQUET_FILE = CSV_FILE.replace('.csv', '.parquet')\n",
    "\n",
    "if os.path.exists(PARQUET_FILE):\n",
    "    article_table = pd.read_parquet(PARQUET_FILE)\n",
    "else:\n",
    "    from sentence_transformers import SentenceTransformer\n",
    "    sentxformer = SentenceTransformer('all-MiniLM-L6-v2')\n",
    "\n",
    "    article_table = pd.read_csv(CSV_FILE).fillna('')\n",
    "    \n",
    "    article_table['section_path_vector'] = sentxformer.encode(article_table['section_path'].values).tolist()\n",
    "    article_table['text_vector'] = sentxformer.encode(article_table['text'].values).tolist()\n",
    "    \n",
    "    article_table.to_parquet(PARQUET_FILE)\n",
    "\n",
    "\n",
    "print(f\"article_table has {len(article_table)} rows.\")\n",
    "\n",
    "article_table.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "eac08016-73c1-4ab2-a3b3-b5e6923e90ed",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('METHODS', 43958),\n",
       " ('RESULTS', 37225),\n",
       " ('DISCUSSION', 27160),\n",
       " ('INTRODUCTION', 17977),\n",
       " ('ABSTRACT', 9446),\n",
       " ('TITLE', 4713),\n",
       " ('CONCLUSIONS', 3670),\n",
       " ('RESULTS AND DISCUSSION', 2424),\n",
       " ('BACKGROUND', 998),\n",
       " ('AUTHOR CONTRIBUTIONS', 750),\n",
       " ('SUPPLEMENTARY INFORMATION', 599),\n",
       " ('DATA AVAILABILITY STATEMENT', 453),\n",
       " ('EXPERIMENTAL SECTION', 385),\n",
       " ('ETHICS STATEMENT', 382),\n",
       " ('CASE PRESENTATION', 366),\n",
       " ('TREATMENT', 257),\n",
       " ('DIAGNOSIS', 254),\n",
       " ('CASE REPORT', 223),\n",
       " ('DECLARATION OF COMPETING INTEREST', 198),\n",
       " ('CONFLICT OF INTEREST', 195),\n",
       " ('FUNDING', 195),\n",
       " ('CONCLUDING REMARKS', 169),\n",
       " ('FUNGAL INFECTIONS', 162),\n",
       " ('SPECIAL CIRCUMSTANCES', 131),\n",
       " ('MAIN TEXT', 127),\n",
       " ('LITERATURE REVIEW', 126),\n",
       " ('ETIOLOGIC DIAGNOSIS: IDENTIFICATION OF THE CULPRIT DRUG', 121),\n",
       " ('DECLARATION OF INTERESTS', 121),\n",
       " ('ASSESSMENT', 120),\n",
       " ('MAIN', 118),\n",
       " ('RESULTS/DISCUSSION', 114),\n",
       " ('EXPERIMENTAL PROCEDURES', 113),\n",
       " ('RESULT', 107),\n",
       " ('LIMITATIONS', 107),\n",
       " ('SYSTEMIC THERAPIES', 104),\n",
       " ('ZOONOSES WITH EPIDEMIOLOGICAL RELEVANCE IN THE MEDITERRANEAN AREA', 100),\n",
       " ('MAINTENANCE TREATMENT', 99),\n",
       " ('EVIDENCE OF ‘SPIKEOPATHY’—SPIKE PROTEIN PATHOGENICITY', 98),\n",
       " ('NATURAL POLYSACCHARIDES WITH IMMUNE-MODULATORY ACTIVITY', 98),\n",
       " ('SEVERE UNCONTROLLED ASTHMA', 96),\n",
       " ('CONTRIBUTORS', 93),\n",
       " ('ELECTRONIC SUPPLEMENTARY MATERIAL', 93),\n",
       " ('INTERVENTIONS', 92),\n",
       " ('CASES', 92),\n",
       " ('MANAGEMENT', 91),\n",
       " ('DISCUSSIONS', 89),\n",
       " ('PUBLISHER’S NOTE', 88),\n",
       " ('THERAPEUTIC MANAGEMENT', 87),\n",
       " ('APPLICATIONS OF CHITOSAN', 84),\n",
       " ('CONFLICT OF INTEREST STATEMENT', 83),\n",
       " ('HOST FACTORS', 83),\n",
       " ('RESULTS AND DISCUSSIONS', 81),\n",
       " ('DRUG THERAPY FOR COVID-19', 81),\n",
       " ('NBTS FOR PROTEIN UPREGULATION', 78),\n",
       " ('MRNA NPS: TARGETING DESIGN STRATEGIES FOR DIFFERENT TISSUES', 75),\n",
       " ('DATA RECORDS', 74),\n",
       " ('SELECTION OF AN ANTIMICROBIAL PRESERVATIVE', 74),\n",
       " ('POTENTIAL POLYSORBATE ALTERNATIVES FOR PROTEIN STABILIZATION IN INJECTABLE FORMULATIONS',\n",
       "  73),\n",
       " ('FINDINGS', 72),\n",
       " ('NANOTECHNOLOGY-BASED OCULAR DRUG DELIVERY SYSTEMS', 72),\n",
       " ('', 71),\n",
       " ('CASE DESCRIPTION', 71),\n",
       " ('ROLE OF THE PI3K-AKT-MTOR AND RELATED NETWORKS IN SKIN DEVELOPMENT AND HOMEOSTASIS',\n",
       "  71),\n",
       " ('INITIAL ASSESSMENT', 69),\n",
       " ('RESULTS AND DISCUSSION—APPLICATIONS OF NANOTECHNOLOGY IN THE MEDICAL FIELD',\n",
       "  69),\n",
       " ('DEMAND FOR HOSPITAL RESOURCES: THE INFINITE SERVER QUEUE', 69),\n",
       " ('VASOPRESSIN', 67),\n",
       " ('BACKGROUND KNOWLEDGE OF CAFS', 66),\n",
       " ('PERSONAL PROTECTIVE EQUIPMENT AND THE GENERATION OF SOLID WASTE DURING THE COVID-19 PANDEMIC',\n",
       "  66),\n",
       " ('CREDIT AUTHORSHIP CONTRIBUTION STATEMENT', 65),\n",
       " ('VACCINES', 65),\n",
       " ('PROTEIN-BASED TARGETING SELF-ASSEMBLING NANOPARTICLES FOR BIOMEDICAL APPLICATIONS',\n",
       "  65),\n",
       " ('CONTRIBUTIONS FROM DIFFERENT COUNTRIES AND REGIONS WORLDWIDE', 64),\n",
       " ('EPIDEMIOLOGY', 63),\n",
       " ('RECOMMENDATIONS [19–30]', 63),\n",
       " ('ETIOLOGICAL AGENTS RESPONSIBLE FOR LUNG INFECTIONS', 63),\n",
       " ('ANIMAL MODELS OF RICIN TOXICITY BY INHALATION', 63),\n",
       " ('CURRENT COVID-19 VACCINE PLATFORMS', 62),\n",
       " ('SUMMARY', 62),\n",
       " ('BIOMATERIALS IN IMMUNOTHERAPY', 62),\n",
       " ('PHARMACOLOGIC AGENTS THAT HAVE BEEN USED AS COVID-19 THERAPY', 62),\n",
       " ('DISCUSSION ', 61),\n",
       " ('ASSESSMENT AND TREATMENT OF ASTHMA EXACERBATIONS', 60),\n",
       " ('MAIN APPLICATIONS OF NANOMATERIALS IN PROTECTION AND RESTORATION PROCESSES AND RISKS OF TOXICITY',\n",
       "  60),\n",
       " ('DESIGN', 59),\n",
       " ('CURRENT APPLICATIONS OF NANOMATERIALS IN VETERINARY MEDICINE', 59),\n",
       " ('PROBIOTICS', 59),\n",
       " ('QUALITATIVE ANALYSIS OF PATIENTS’ INTERVIEWS', 59),\n",
       " ('FROM RESEARCH TO REAL-WORLD EXPERIENCE: CURRENTLY APPROVED AND CLINICAL DEVELOPMENT OF EXPERIMENTAL VACCINES AGAINST ANTIBIOTIC-RESISTANT BACTERIA',\n",
       "  58),\n",
       " ('REASONS FOR CONCERN: PHARMACODYNAMIC, PHARMACOKINETIC, AND PATHOPHYSIOLOGICAL',\n",
       "  58),\n",
       " ('DROPLET FORMATION MECHANISMS', 58),\n",
       " ('SUMMARY OF SCIENTIFIC SESSIONS', 57),\n",
       " ('FUTURE DIRECTIONS', 56),\n",
       " ('INNATE IMMUNE CELL SUBSETS', 55),\n",
       " ('COMPUTER MODELLING OF PARTICLES AND BIOLOGICAL AGENTS’ AIRBORNE TRANSMISSION INTO INDOOR BUILT ENVIRONMENT',\n",
       "  55),\n",
       " ('PROTEIN/PEPTIDE THERAPEUTICS THAT ARE ENHANCED THROUGH CHEMICAL MODIFICATION',\n",
       "  54),\n",
       " ('NOVEL STRATEGIES TO COMBAT AMR', 54),\n",
       " ('ANTIBODY THERAPEUTICS UNDERGOING FIRST REGULATORY REVIEW IN THE US OR EU',\n",
       "  54),\n",
       " ('DATA SHARING STATEMENT', 53),\n",
       " ('INDIVIDUAL DRUG GROUPS IMPLICATED IN REACTIONS', 53),\n",
       " ('RESULTS\\nAND DISCUSSION', 53),\n",
       " ('COMPOUNDS UNDERGOING CLINICAL EVALUATION', 53),\n",
       " ('ANIMAL FARMING AND ASSOCIATED SOURCES OF CONTAMINATION (MICROBIAL AND CHEMICAL CONTAMINATION)',\n",
       "  53),\n",
       " ('ASTHMA-ASSOCIATED RHINITIS AND RHINOSINUSITIS', 52),\n",
       " ('EFFICACY OF KD IN COVID-19', 52),\n",
       " ('RELEASE OF GPI-APS', 52),\n",
       " ('BIOLOGICAL AND PHARMACOLOGICAL ACTIVITIES OF BERGENIN', 52),\n",
       " ('USAGE NOTES', 51),\n",
       " ('EXPERIMENTAL RESULTS', 51),\n",
       " ('ALLERGIC FUNGAL DISEASES', 51),\n",
       " ('ACKNOWLEDGMENTS', 50),\n",
       " ('THE CLINICAL PIPELINE OF TB VACCINES', 50),\n",
       " ('TREATMENT OF CHILDHOOD ASTHMA', 50),\n",
       " ('GLUCOCORTICOIDS (GCS)', 50),\n",
       " ('ANTIBODIES TO WATCH IN 2023: CANCER INDICATIONS', 50),\n",
       " ('TACE AND RADIOEMBOLIZATION', 50),\n",
       " ('AUTHOR CONTRIBUTION STATEMENT', 49),\n",
       " ('APPROACHES TO AND APPARATUS OF THERAPEUTIC VACCINATION IN HNSCC', 49),\n",
       " ('FRACTIONATION OF EGG PROTEINS', 49),\n",
       " ('ANTIBODIES IN DIFFERENT BRANCHES OF MEDICINE', 49),\n",
       " ('NATURALLY OCCURRING T3SS INHIBITORS', 49),\n",
       " ('RECOMMENDATIONS FOR THE PROPER HANDLING AND STORAGE OF NANOMATERIALS: STATE OF THE ART',\n",
       "  49),\n",
       " ('FRAMEWORK', 48),\n",
       " ('LEISHMANIASIS: IMMUNE CELLS CROSSTALK IN MACROPHAGE POLARIZATION', 48),\n",
       " ('STATISTICAL ANALYSIS', 47),\n",
       " ('CHARACTERISTICS OF AN IDEAL MODEL RECAPITULATING HEV INFECTION IN HUMANS',\n",
       "  47),\n",
       " ('VIRUSES ASSOCIATED WITH ONCOGENESIS', 47),\n",
       " ('IN VIVO APPLICATIONS OF HOCL', 47),\n",
       " ('PORPHYRINS', 47),\n",
       " ('MOLECULAR MEDIATORS OF INFLAMMATION IN ZEBRAFISH', 47),\n",
       " ('LIVER TRANSPLANTATION', 46),\n",
       " ('LONG COVID ASSESSMENT IN CHILDREN', 46),\n",
       " ('RESULTS:', 45),\n",
       " ('THERAPEUTICS THAT ARE ENHANCED BY PROTEIN CONJUGATION', 45),\n",
       " ('NANO-DRUG THERAPY', 45),\n",
       " ('ETIOLOGY', 45),\n",
       " ('EXTRACTION OF POLYSACCHARIDES', 45),\n",
       " ('APPLICATIONS OF PHLOROTANNINS', 45),\n",
       " ('BIOMEDICAL APPLICATIONS OF BIO-INSPIRED NANOMATERIALS IN MICRO/NANODEVICES',\n",
       "  45),\n",
       " ('THE INTERPLAY BETWEEN MAIN MOLECULAR AND CELLULAR PATHOGENIC MECHANISMS IN PEDIATRIC LONG COVID',\n",
       "  45),\n",
       " ('NOVEL IMMUNE-ENHANCED ANTIMICROBIAL STRATEGIES', 45),\n",
       " ('OPTICALLY ACTIVE NANOMATERIALS AND ITS TYPES: BASED ON THEIR CHEMICAL COMPOSITIONS',\n",
       "  45),\n",
       " ('OVERVIEW AND APPLICATIONS OF CARBON-BASED NANOMATERIALS AS ANTIMICROBIALS',\n",
       "  45),\n",
       " ('FUNDING INFORMATION', 44),\n",
       " ('FUTURE PERSPECTIVES', 44),\n",
       " ('THE JOURNEY OF NPS WITHIN THE BODY', 44),\n",
       " ('DRUG DELIVERY SYSTEMS BASED ON ORGANIC POLYMERS AND LAYERED DOUBLE HYDROXIDES NANOCOMPOSITES',\n",
       "  44),\n",
       " ('ANTIBODY THERAPEUTICS FIRST APPROVED OR UNDERGOING REGULATORY REVIEW OUTSIDE THE US OR EU IN 2022',\n",
       "  44),\n",
       " ('SYNTHETIC POLYMERS', 44),\n",
       " ('HEPATIC RESECTION', 44),\n",
       " ('LOCAL ABLATION THERAPIES', 44),\n",
       " ('NON-HORMONAL CONTRACEPTIVES IN DEVELOPMENT', 44),\n",
       " ('PREAMBLE', 44),\n",
       " ('RESISTANCE MECHANISMS TO TARGETED AGENTS IN MCRC', 44),\n",
       " ('CHITIN SYNTHASES IN ASPERGILLUS SPECIES', 43),\n",
       " ('ANTIBODY THERAPEUTICS GRANTED A FIRST APPROVAL IN THE US OR EU IN 2022',\n",
       "  43),\n",
       " ('THERAPEUTIC EFFICACY OF REMDESIVIR', 43),\n",
       " ('DISCUSSION AND SAFETY REVIEW', 43),\n",
       " ('BIOMATERIALS AND ANTIMICROBIAL AGENTS FOR CHRONIC WOUND CARE', 43),\n",
       " ('DISCUSSION:', 42),\n",
       " ('AEROSOLS AND BIOAEROSOLS', 42),\n",
       " ('NON-ESSENTIAL AMINO ACIDS', 42),\n",
       " ('SYNTHESIZED INHIBITORS OF T3SSS', 42),\n",
       " ('COMMENTARY', 42),\n",
       " ('IMMUNOTHERAPEUTICS', 41),\n",
       " ('OVERSIGHT AND MONITORING', 41),\n",
       " ('THE PENETRATION OF NPS THROUGH THE SKIN', 41),\n",
       " ('BIOCULTURAL AND GASTRONOMIC IMPORTANCE OF HUITLACOCHE', 41),\n",
       " ('INORGANIC NANOPARTICLES FOR SKIN CANCER THERAPY', 41),\n",
       " ('PREVENTION', 41),\n",
       " ('RBC-DERIVED EXTRACELLULAR VESICLES (RBCEVS): BIOGENESIS AND COMPOSITION',\n",
       "  41),\n",
       " ('ET-1 IN DISEASE', 41),\n",
       " ('INTERACTION OF NANOMATERIALS WITH THE HUMAN BODY', 41),\n",
       " ('PEPTIDE VACCINES DEVELOPED FOR FEMALE-SPECIFIC CANCERS', 40),\n",
       " ('BODY', 40),\n",
       " ('DEFINE DECISION MAKING PROBLEM OF COVID-19 TREATMENTS IN INDIA', 40),\n",
       " ('IMMUNOGLOBULIN (IG)-COATING OF BACTERIA IN THE GUT IN CONDITIONS WITH REDUCED MICROBIOTA DIVERSITY (DYSBIOSIS), CONDITIONS POTENTIALLY MODIFIED BY MICROBIAL RESTORATION WITH FECAL MICROBIOTA TRANSPLANTATION',\n",
       "  40),\n",
       " ('VIRAL TARGETS FOR ANTIVIRAL AGENTS', 40),\n",
       " ('BASIC KNOWLEDGE OF PHAGOCYTOSIS CHECKPOINTS', 40),\n",
       " ('SKIN DISEASES IN BRACHYCEPHALIC BREEDS THAT ARE NOT DIRECTLY LINKED WITH BRACHYCEPHALIC CONFORMATION',\n",
       "  39),\n",
       " ('THE INTERPLAY BETWEEN MICROBIOTA AND CANCER TREATMENT', 39),\n",
       " ('THE STUDY', 39),\n",
       " ('CONTROL CHALLENGES', 39),\n",
       " ('PROTEIN- AND PEPTIDE-BASED THERAPEUTICS EMPLOYING SILICA-BASED NANOSYSTEMS',\n",
       "  39),\n",
       " ('ORGAN-SPECIFIC INFLAMMATORY DISEASES', 39),\n",
       " ('IN RESPONSE TO REVIEWERS’ COMMENTS', 39),\n",
       " ('EXPERIMENTAL', 39),\n",
       " ('CHITOSAN-BASED NANOPARTICLES FOR PULMONARY DELIVERY', 39),\n",
       " ('TROUBLESHOOTING', 38),\n",
       " ('FUNCTIONAL FOODS AS IMMUNE FITNESS BOOSTERS IN THE CONTEXT OF VIRAL INFECTION',\n",
       "  38),\n",
       " ('IVT-MRNA DELIVERY MEDIATED BY PTD TECHNOLOGY', 38),\n",
       " ('PARACOCCIDIODOMYCOSIS', 38),\n",
       " ('EXTRACELLULAR VESICLES: AN OVERVIEW OF THEIR ORIGIN AND COMPOSITION', 38),\n",
       " ('BIOMEDICAL APPLICATIONS OF CELL MEMBRANE CAMOUFLAGED PLGA NPS\\n', 38),\n",
       " ('STRUCTURE, PATHOLOGY, AND IMMUNE RESPONSE', 37),\n",
       " ('THERAPEUTIC AGENTS', 37),\n",
       " ('THE INTERACTION OF NANOPARTICLES WITH COMPONENTS OF IMMUNE SYSTEM', 37),\n",
       " ('MANAGEMENT OF COVID-19 IN PWH', 37),\n",
       " ('THE HUMAN MICROBIOME AND CANCER', 37),\n",
       " ('EVALUATION OF HOST-DERIVED BIOMARKERS', 37),\n",
       " ('STRESS, PTSD, AND OBESITY-RELATED MORBIDITIES', 37),\n",
       " ('LIPID-BASED CARRIER SYSTEMS', 37),\n",
       " ('FUTURE PERSPECTIVE', 36),\n",
       " ('CHALLENGES AND PROSPECTS IN THE RESEARCH OF NOVEL TB VACCINES', 36),\n",
       " ('CLINICAL TRIALS', 36),\n",
       " ('NEW THERAPEUTIC OPTIONS', 36),\n",
       " ('EMPIRICAL RESULTS', 36),\n",
       " ('LONG COVID IMPACT ON THE HEALTH OF CHILDREN AND ADOLESCENTS', 36),\n",
       " ('THE SOURCE OF BIOFLUIDS AND CONTINUOUS SENSING TECHNOLOGIES', 36),\n",
       " ('LONG COVID: A CONCISE CONTEXTUAL FUTURE', 36),\n",
       " ('BIOLOGICAL FUNCTIONS OF INSECT ACTIVE INGREDIENTS', 36),\n",
       " ('CLINICAL TRIALS OF SKIN CANCER CHEMOPREVENTION', 36),\n",
       " ('INFLAMMATION-REPRESSING PROTEINS', 36),\n",
       " ('THE FACTORS AFFECTING THE EFFICIENCY OF LNP@MRNA DELIVERY', 35),\n",
       " ('TREATMENTS UNDER DEVELOPMENT', 35),\n",
       " ('DATA COLLECTION AND MANAGEMENT', 35),\n",
       " ('LF AND LFC IN HOST DEFENSE', 35),\n",
       " ('CASE 1: CHRONIC MIGRAINE WITH MEDICATION OVERUSE', 35),\n",
       " ('FERROPTOSIS', 35),\n",
       " ('DETERIORATION OF CULTURAL HERITAGE MATERIALS', 35),\n",
       " ('ROLE OF INTERNATIONAL ORGANIZATIONS IN THE CONTROL OF EXPOSURE TO NANOMATERIALS AND THE ASSESSMENT OF THE DEGREE OF TOXICITY',\n",
       "  35),\n",
       " ('PHARMACOLOGICAL ACTIVITY', 35),\n",
       " ('MOLECULAR MECHANISMS AND SIGNALING PATHWAYS GOVERNED BY INFLAMMATORY MEDIATORS IN ZEBRAFISH',\n",
       "  35),\n",
       " ('VACCINE DEVELOPMENT', 34),\n",
       " ('INTRODUCTION\\n', 34),\n",
       " ('RESULT AND DISCUSSION', 34),\n",
       " ('NEW DISCOVERED MOLECULES', 34),\n",
       " ('LNP DESIGN PRINCIPLES', 34),\n",
       " ('CHARGE-BASED TARGETING APPROACHES', 34),\n",
       " ('FUNGAL INFECTIONS IN COVID-19 PATIENTS', 34),\n",
       " ('CELL MEMBRANE CAMOUFLAGED PLGA NPS\\n', 34),\n",
       " ('TICK-BORNE ZOONOSES OF NORTH AFRICA', 34),\n",
       " ('M. TUBERCULOSIS AND INNATE IMMUNITY', 34),\n",
       " ('OXALIPLATIN, A THIRD ATTEMPT', 34),\n",
       " ('CASE 6: NEUROSYPHILIS PRESENTING WITH PSYCHOTIC SYMPTOMS', 34),\n",
       " ('EUBIOTICS: DRUGS TO MODULATE THE GUT MICROBIOTA', 34),\n",
       " ('ETHICS AND DISSEMINATION', 33),\n",
       " ('DECLARATIONS', 33),\n",
       " ('SARS-COV-2 VACCINE-ASSOCIATED MYOCARDITIS AND MYOCARDIAL INJURY', 33),\n",
       " ('CTA SUBFAMILIES', 33),\n",
       " ('ANALYSIS, RESULTS, AND DISCUSSIONS', 33),\n",
       " ('HUMAN MICROBIOTA, DYSBIOSIS, AND CANCER', 33),\n",
       " ('DEVELOPMENT OF SILICA-BASED NANOMEDICINES USING THERAPEUTIC NUCLEOTIDES',\n",
       "  33),\n",
       " ('LIMITATIONS IN THE THERAPEUTIC USE OF EXOSOMES', 33),\n",
       " ('RECENT ADVANCES IN MICROBIAL SENSING', 33),\n",
       " ('MITOCHONDRIA AND INNATE AND ADAPTIVE IMMUNITY INDUCED BY IR', 33),\n",
       " ('SPATIAL METRICS', 33),\n",
       " ('DATA AVAILABILITY', 32),\n",
       " ('TYPES OF ADJUVANTS', 32),\n",
       " ('NANOTECHNOLOGICAL APPROACH FOR COMBATING TB', 32),\n",
       " ('LAYERED DOUBLE HYDROXIDES: STRUCTURE, PHYSICOCHEMICAL PROPERTIES, BIOCOMPATIBILITY',\n",
       "  32),\n",
       " ('NON-VIRAL GENE VECTOR', 32),\n",
       " ('SCREENING TESTS FOR TBI', 32),\n",
       " ('ANGOLA’S VARIABLE MALARIA INCIDENCE RATES AND FACTORS THAT CONTRIBUTE TO STRATIFICATION',\n",
       "  32),\n",
       " ('OP-MEDIATED MODULATION OF THE IMMUNE RESPONSE', 32),\n",
       " ('NANOTECHNOLOGIES AND LUNG CANCER THERAPY', 32),\n",
       " ('CISPLATIN: THE FIRST PLATINATING AGENT', 32),\n",
       " ('A STEPWISE APPROACH TO PROVIDING PEP', 32),\n",
       " ('MOST SUCCESSFUL APPLICATION OF PLGA PARTICLES IN IMMUNOTHERAPY', 31),\n",
       " ('PLANT VIRUSES AS ADJUVANTS IN VACCINES AND IMMUNOTHERAPY', 31),\n",
       " ('COHORT DESCRIPTION', 31),\n",
       " ('GENERAL DISCUSSION', 31),\n",
       " ('IMMUNOTHERAPY IN BREAST CANCER MANAGEMENT', 31),\n",
       " ('APPLICATION OF BIOMIMETIC CELL-DERIVED NANOPARTICLES IN CANCER IMMUNOTHERAPY',\n",
       "  31),\n",
       " ('DEVELOPMENT OF NITROHETEROCYCLIC DRUGS AGAINST TRYPANOSOMES', 31),\n",
       " ('NATURAL POLYMERS', 31),\n",
       " ('VITREORETINAL DISEASES', 31),\n",
       " ('POLYSACCHARIDE DRUG CARRIERS', 31),\n",
       " ('EXOSOME-BASED THERAPEUTIC STRATEGIES FOR RA', 31),\n",
       " ('THE MECHANISM BY WHICH M1- AND M2-POLARIZED MACROPHAGES PROMOTE OR INHIBIT THE GROWTH OF GLIOBLASTOMA',\n",
       "  31),\n",
       " ('ROLE OF EXTRACELLULAR VESICLES IN PRE-METASTATIC NICHE FORMATION AND METASTATIC DISSEMINATION',\n",
       "  31),\n",
       " ('MESOPOROUS SILICA NANOPARTICLES (MSN)', 31),\n",
       " ('INGESTION', 30),\n",
       " ('OMALIZUMAB', 30),\n",
       " ('SARS-COV-2 VARIANTS', 30),\n",
       " ('OTHER INFLAMMATORY CONDITIONS', 30),\n",
       " ('SALIVARY D7 PROTEINS ARE ANTI-INFLAMMATORY AND ANTI-HEMOSTATIC MOLECULES',\n",
       "  30),\n",
       " ('FABRICATION AND CURRENT STATUS OF MICRONEEDLES', 30),\n",
       " ('THE ROLE OF LACTOFERRIN IN LUNG DISEASES', 30),\n",
       " ('IMMUNOMODULATION', 30),\n",
       " ('EXOSOME', 30),\n",
       " ('DEVELOPED DRUGS TARGETING AΒ AND TAU FOR AD THERAPY', 30),\n",
       " ('TARGETING PHAGOCYTOSIS CHECKPOINTS AND CLINICAL APPLICATIONS', 30),\n",
       " ('TYPES OF DRUGS', 30),\n",
       " ('MECHANISMS OF ACTION', 30),\n",
       " ('INFECTIOUS DISEASES CAUSING SYMPTOMATOLOGY AND MORTALITY\\xa0WITH DEMOGRAPHIC IMPACT IN IBERIAN IBEX POPULATIONS',\n",
       "  30),\n",
       " ('APPENDIX', 30),\n",
       " ('THERAPEUTIC STRATEGIES FOR CHRONIC IMMUNE-MEDIATED INFLAMMATORY SKIN DISORDERS',\n",
       "  30),\n",
       " ('ANTIVIRAL THERAPY AGAINST COVID-19', 29),\n",
       " ('STRUCTURE AND FUNCTION OF KIF20A', 29),\n",
       " ('VACCINE', 29),\n",
       " ('STUDY PROCEDURES', 29),\n",
       " ('RELATED WORK', 29),\n",
       " ('DISCUSSION [31–37]', 29),\n",
       " ('REPURPOSED DRUGS', 29),\n",
       " ('PATHOGENESIS OF LISTERIOSIS', 29),\n",
       " ('PERIODONTAL PATHOGENS, VIRULENCE FACTORS AND HOST RESPONSE', 29),\n",
       " ('DRUGS THAT TARGET IMMUNOMODULATORY PATHWAYS', 29),\n",
       " ('CAUSES OF INSTABILITY', 29),\n",
       " ('COMBINATION USE OF NANOTECHNOLOGY AND OTHER NEW TECHNIQUES FOR OCULAR DRUG DELIVERY',\n",
       "  29),\n",
       " ('CASE 4: BIPOLAR AFFECTIVE DISORDER WITH NORMAL PRESSURE HYDROCEPHALUS', 29),\n",
       " ('HOST IMMUNE RESPONSE TO IMPLANTED ANTIBACTERIAL BIOMATERIALS ', 29),\n",
       " ('ABBREVIATIONS', 28),\n",
       " ('ONLINE CONTENT', 28),\n",
       " ('VACCINE CANDIDATES', 28),\n",
       " ('MRNA VACCINES', 28),\n",
       " ('REVIEW', 28),\n",
       " ('ESSENTIALS', 28),\n",
       " ('CHALLENGES AND PERSPECTIVES', 28),\n",
       " ('GENERAL INFORMATION', 28),\n",
       " ('TRAINED IMMUNITY', 28),\n",
       " ('AUTOINFLAMMATORY URTICARIAL SYNDROMES', 28),\n",
       " ('ACTIVE IMMUNOTHERAPY', 28),\n",
       " ('PATHOGENESIS', 28),\n",
       " ('ACCUMULATION OF STATISTICAL DATA OF COVID-19 COMPONENTS AND THEIR INTERPRETATIVE ANALYSIS',\n",
       "  28),\n",
       " ('CURRENT TREATMENTS AGAINST TRYPANOSOMATIDS', 28),\n",
       " ('MICRONUTRIENTS: VITAMINS AND MINERALS', 28),\n",
       " ('CHITOSAN NANOPARTICLES', 28),\n",
       " ('DRUG TREATMENT FOR CANCER PAIN IN HCC', 28),\n",
       " ('QUANTIFYING TRANSMISSION IN A PLACE', 28),\n",
       " ('BIOPHARMACOLOGICAL MODES OF ACTION', 28),\n",
       " ('NANO-ANTIBACTERIAL MATERIALS', 28),\n",
       " ('OCULAR INFECTIONS CAUSED BY VIRUSES', 28),\n",
       " ('CURRENT PRECLINICAL AND CLINICAL DEVELOPMENT OF NEXT-GENERATION VACCINES AGAINST AMR BACTERIA',\n",
       "  27),\n",
       " ('UPDATES IN ACUTE CARE', 27),\n",
       " ('CONFLICTS OF INTEREST', 27),\n",
       " ('SYSTEMATIC REVIEW OF HUMAN CHALLENGE STUDIES USING\\nM. TUBERCULOSIS\\n', 27),\n",
       " ('COMPONENTS OF BACTERIAL EVS', 27),\n",
       " ('FEATURE EXTRACTION ALGORITHMS IN NEOANTIGEN PREDICTION', 27),\n",
       " ('INTERACTIONS BETWEEN ANTIMICROBIAL PRESERVATIVES AND BIOLOGICAL COMPOUNDS',\n",
       "  27),\n",
       " ('LIPOSOMAL FORMULATION PERFORMANCE: CHARACTERISTICS, FUNCTIONALIZATION AND INTERNALIZATION',\n",
       "  27),\n",
       " ('OTHER DISEASES', 27),\n",
       " ('INTRAPULMONARY INFECTION MECHANISM', 27),\n",
       " ('THE POTENTIAL OF PROBIOTIC MICROORGANISMS ISOLATED FROM FOOD', 27),\n",
       " ('FACTORS DETERMINING THE STABILITY OF PROBIOTICS', 27),\n",
       " ('CURRENT THERAPEUTIC APPROACHES TO TREAT SEPSIS', 27),\n",
       " ('VASOPRESSIN-RELATED POSSIBLE THERAPIES IN AUTISM', 27),\n",
       " ('GASTROESOPHAGEAL REFLUX DISEASE (GERD)', 27),\n",
       " ('MODULATING THE HOST RESPONSE TO SEPSIS', 27),\n",
       " ('IMPACT OF DIETARY AND ENDOGENOUS LIPIDS ON THE INTESTINAL MUCOSAL AND SYSTEMIC IMMUNE SYSTEMS',\n",
       "  27),\n",
       " ('PREVENTION OF VIRAL RESPIRATORY INFECTIONS', 26),\n",
       " ('THERAPEUTIC OPTIONS', 26),\n",
       " ('APPLICATION OF FERRITIN-BASED NANOMEDICINE', 26),\n",
       " ('CANCER PHARMACOTHERAPY—MANAGEMENT OF SIDE EFFECTS BY ORGAN SITE', 26),\n",
       " ('ANTIVIRAL NANOMATERIALS WITH NATURAL ORIGINS', 26),\n",
       " ('THE DANIO RERIO MODEL', 26),\n",
       " ('NANODRUGS FOR THE TREATMENT OF LIVER DISEASE', 26),\n",
       " ('ORGANIC POLYMERS AND LAYERED DOUBLE HYDROXIDES NANOCOMPOSITES FOR TISSUE ENGINEERING',\n",
       "  26),\n",
       " ('ANTI-INFLAMMATORY PROPERTIES', 26),\n",
       " ('DIFFERENT DELIVERY PLATFORMS FOR MONOCLONAL ANTIBODIES', 26),\n",
       " ('CLINICAL MANIFESTATIONS', 26),\n",
       " ('SYNTHESIS OF BIO-INSPIRED BIOMEDICAL NANOMATERIALS', 26),\n",
       " ('DESIGN PRINCIPLES OF BIO-INSPIRED NANOMATERIALS’ INTERFACES', 26),\n",
       " ('RESPIRATORY INFECTIONS IN THE AGING LUNG', 26),\n",
       " ('ANTIBACTERIAL PROPERTIES OF CAPSAICIN', 26),\n",
       " ('MANAGEMENT OF IBD DURING PREGNANCY', 26),\n",
       " ('FORMULATION OF INFANT FORMULA: INGREDIENTS AND NUTRIENTS', 26),\n",
       " ('PHARMACEUTICS APPLICATIONS OF SELF-ASSEMBLED PEPTIDES', 26),\n",
       " ('PARASITES OF ECONOMIC IMPORTANCE', 26),\n",
       " ('STRATEGIES IN THE STABILIZATION ', 26),\n",
       " ('NANOTECHNOLOGY-BASED VORICONAZOLE DELIVERY SYSTEMS', 26),\n",
       " ('CONTENTS', 26),\n",
       " ('PARENTERAL ROUTE', 26),\n",
       " ('THE MAIN ELEMENTS OF PDT AND MELANOMA', 26),\n",
       " ('TREATMENT STRATEGIES FOR TNBC', 26),\n",
       " ('ANTIVIRAL ACTIONS OF ISOQUINOLINE RELATED ALKALOIDS', 26),\n",
       " ('RELEVANT SECTIONS', 26),\n",
       " ('ACIDOPHILIC LACTIC ACID BACTERIA’S ROLE IN THE HUMAN DIET AND HEALTH', 26),\n",
       " ('EFFECTIVE BINDING OF GLYCYRRHIZIN AND RELATED TERPENOIDS WITH SARS-COV-2 PROTEIN TARGETS: THEORETICAL AND HYPOTHETICAL EVIDENCES',\n",
       "  26),\n",
       " ('SOURCE DATA', 25),\n",
       " ('RESULTS.', 25),\n",
       " ('STUDY DESIGN', 25),\n",
       " ('DYSREGULATION OF MICROBIOME–IMMUNITY INTERACTION IN VARIOUS DISEASES', 25),\n",
       " ('DESIGN OF HYBRID POLYMER-PROTEIN SYSTEMS', 25),\n",
       " ('ANIMAL MODELS', 25),\n",
       " ('CELL CULTURE', 25),\n",
       " ('DERMATOLOGIC PATTERNS', 25),\n",
       " ('THE QUALITY STANDARDS OF CARE STATEMENTS', 25),\n",
       " ('HOST CELL MECHANISMS THAT CONTROL INFECTION AND REPLICATION', 25),\n",
       " ('PATHOPHYSIOLOGY OF CHAGAS CARDIOMYOPATHY', 25),\n",
       " ('OCULAR SURFACE DISEASES', 25),\n",
       " ('THE ROLE OF HEATING, VENTILATION AND AIR-CONDITIONING SYSTEMS', 25),\n",
       " ('DIAGNOSIS OF MYOCARDITIS', 25),\n",
       " ('ROLE OF HA IN CANCER PROGRESSION', 25),\n",
       " ('MICRONEEDLES-ASSISTED TUMOR THERAPY', 25),\n",
       " ('NANOMATERIAL-BASED DRUG DELIVERY SYSTEMS ARE A PROMISING APPROACH FOR THE TREATMENT OF OPHTHALMOLOGY DISEASES',\n",
       "  25),\n",
       " ('TO CURRENT: CONTEMPORARY INVESTIGATIONS ON DIVERSE SOURCE-EXPOSURE SCENARIOS',\n",
       "  25),\n",
       " ('GROUP 1: DMS DENOTING LIFE-THREATENING SKIN DISEASES THAT REQUIRE ICU ADMISSION',\n",
       "  25),\n",
       " ('HOCL – A NATURAL BIOCIDE', 25),\n",
       " ('NON-PORPHYRIN PHOTOSENSITIZERS', 25),\n",
       " ('BIOLOGICAL ACTIVITIES OF FUCO-OLIGOSACCHARIDES', 25),\n",
       " ('MECHANISMS CAUSING GASTRIC CANCER FROM THE SYNERGISTIC INFLUENCE OF A HIGH-SALT DIET WITH H. PYLORI INFECTION',\n",
       "  25),\n",
       " ('IAS', 25),\n",
       " ('CONSENT', 24),\n",
       " ('VACCINES AND URTICARIA', 24),\n",
       " ('INTRODUCTION:', 24),\n",
       " ('BEFORE YOU BEGIN', 24),\n",
       " ('NANO-ADJUVANTS', 24),\n",
       " ('BIOACTIVE PEPTIDES DERIVED FROM EGG PROTEIN', 24),\n",
       " ('LIPID CARRIERS FOR MRNA DELIVERY', 24),\n",
       " ('NONSPECIFIC IMMUNOMODULATION', 24),\n",
       " ('RESULTS1', 24),\n",
       " ('VKH DISEASE AND COVID-19 VACCINES', 24),\n",
       " ('BOOSTING IMMUNE FITNESS IN HIGH-RISK INDIVIDUALS', 24),\n",
       " ('THE SARS COV-2 S PROTEIN AND AUTOIMMUNITY', 24),\n",
       " ('EVOLUTION OF DRUG DELIVERY SYSTEMS AND THE EMERGENCE OF NANOTECHNOLOGY IN CLINICAL TREATMENTS',\n",
       "  24),\n",
       " ('THE MICROBIOTA AS TARGET THERAPY', 24),\n",
       " ('EVALUATION OF MTB-DERIVED BIOMARKERS', 24),\n",
       " ('TRENDS IN PUSH FUNDING', 24),\n",
       " ('ADVANTAGES OF NANOPARTICLES OVER CONVENTIONAL THERAPIES', 24),\n",
       " ('POLYMERIC NANOPARTICLES', 24),\n",
       " ('RESULTS AND ANALYSIS', 24),\n",
       " ('A POTENTIAL FRAMEWORK THAT INCREASES THE ODDS OF THE GENETIC RECOMBINATION AS ENVISIONED BY AMBATI ET AL.',\n",
       "  24),\n",
       " ('ENERGETICS OF VIRAL\\xa0STRUCTURES', 24),\n",
       " ('REGULATION OF IMMUNE CELL FUNCTION BY MSC-EVS', 24),\n",
       " ('SINONASAL SARS-COV-2 INFECTION', 24),\n",
       " ('CASE 3: REFRACTORY EPILEPTIC SEIZURES WITH SUBJECTIVE SENSORY SYMPTOMS',\n",
       "  24),\n",
       " ('BINDING AFFINITY AND KINETICS', 24),\n",
       " ('HUMAN HEALTH-PROMOTING EFFECTS OF SELENIUM', 24),\n",
       " ('IMMUNE CELL PATHWAYS', 24),\n",
       " ('CURRENT MARKETS FOR MICROALGAE AS FOOD', 24),\n",
       " ('TECHNICAL VALIDATION', 23),\n",
       " ('SUPPLEMENTARY DATA', 23),\n",
       " ('ADJUVANT', 23),\n",
       " ('THE IMMUNE RESPONSE TO THE SARS-COV-2 AND TO THE MRNA VACCINES', 23),\n",
       " ('PEG–LIPID STRUCTURE, CORRELATION TO IMMUNOGENICITY AND\\nEFFICIENCY', 23),\n",
       " ('ETHICAL APPROVAL', 23),\n",
       " ('THE FRENCH COVID COHORT STUDY GROUP', 23),\n",
       " ('CLINICAL APPLICATIONS OF VΔ2 T CELL IMMUNOTHERAPY', 23),\n",
       " ('THE EFFECTS OF SEX HORMONES', 23),\n",
       " ('AUTOIMMUNE DISORDERS', 23),\n",
       " ('TARGETED THERAPY', 23),\n",
       " ('H. PYLORI VIRULENCE FACTORS AND CANCER MECHANISMS', 23),\n",
       " ('CURRENT STRATEGIES AND FUTURE PERSPECTIVES FOR TIME-TARGETING TREATMENT',\n",
       "  23),\n",
       " ('NANOPARTICLES IN PHARMACEUTICAL APPLICATION PERSPECTIVES', 23),\n",
       " ('MODEL AND RESULTS', 23),\n",
       " ('OMVS', 23),\n",
       " ('RBCS AND THEIR DERIVATIVES IN THE DELIVERY SYSTEM', 23),\n",
       " ('ALDHS AS CSC AND PROGNOSIS MARKERS IN TUMORS', 23),\n",
       " ('THE INFLUENCE AND INVOLVEMENT OF IBD IN REPRODUCTION', 23),\n",
       " ('EMERGING BIOMARKER LANDSCAPE IN PTCL AND NKTCL', 23),\n",
       " ('SELF-ASSEMBLED PEPTIDE DESIGNS AND HYDROGEL CONSTRUCTION', 23),\n",
       " ('WHAT IMMUNOSUPPRESSIVE THERAPIES ARE USED FOR ILDS?', 23),\n",
       " ('INVASIVE ASPERGILLOSIS', 23),\n",
       " ('WEARABLE MONITORING OF DRUGS', 23),\n",
       " ('DEVELOPMENTS IN THE IMMUNOTHERAPY OF NEUROLOGICAL DISORDERS', 23),\n",
       " ('ESSENTIAL AMINO ACIDS', 23),\n",
       " ('TARGETED THERAPIES', 23),\n",
       " ('GROUP 3: DMS ASSOCIATED WITH SYSTEMIC DISEASES ', 23),\n",
       " ('SAFETY – HOCL TISSUE COMPATIBILITY AND TOLERANCE', 23),\n",
       " ('DISRUPTIVE INFORMATION TECHNOLOGIES FOR DRUG MANAGEMENT: RELATED WORK', 23),\n",
       " ('MICROBIOTA, BRANCHED CHAINED AMINO ACIDS AND OBESITY', 23),\n",
       " ('BIOLOGICAL ACTIVITY', 23),\n",
       " ('GOOD USE OF ANTIBIOTICS IN CHILDREN', 23),\n",
       " ('DATA SHARING', 22),\n",
       " ('INTERPRETATION OF STUDIES ASSESSING OIT EFFICACY', 22),\n",
       " ('CURCUMIN AND VIRUS INFECTIONS', 22),\n",
       " ('CHIKV RESEARCH: INDIAN SCENARIO', 22),\n",
       " ('IMMUNE CELLS IN THE NSCLC TME AND THEIR RELATIONSHIP WITH DCS', 22),\n",
       " ('CURRENT ONGOING CLINICAL TRIALS ON MPX VIRUS', 22),\n",
       " ('PROGRAM PLAN', 22),\n",
       " ('ROLE OF IL-21 IN GB: SIGNIFICANCE AND EFFECTIVENESS OF IMMUNOTHERAPY', 22),\n",
       " ('ANTIBODY PREPARATIONS', 22),\n",
       " ('METHOTREXATE (MTX)', 22),\n",
       " ('MOLECULAR TARGETED THERAPEUTIC APPROACHES IN MITIGATING CRPC', 22),\n",
       " ('PHARMACOLOGICAL TREATMENT OF ASTHMA', 22),\n",
       " ('RECENT TECHNOLOGIES FOR IN VITRO STUDIES ON IN DRUGS', 22),\n",
       " ('CURRENT CHALLENGES AND FUTURE DIRECTIONS', 22),\n",
       " ('IMAGING OF IMMUNE-RELATED ADVERSE EVENTS', 22),\n",
       " ('FINDINGS TO DATE', 22),\n",
       " ('COVID-19 AND HEPATITIS B AND C INFECTION', 22),\n",
       " ('ANTIMICROBIAL THERAPIES', 22),\n",
       " ('FACTORS TO CONSIDER IN THE CONSUMPTION OF EDIBLE INSECTS', 22),\n",
       " ('INNATE IMMUNE CELLULAR COMPONENTS', 22),\n",
       " ('NKT-LIKE CELLS: ROLE IN DISEASE', 22),\n",
       " ('TOPICAL NANO-FORMULATIONS FOR OCULAR DRUG DELIVERY', 22),\n",
       " ('PHAGOCYTOSIS CHECKPOINTS IN DISEASES AND THE TUMOR MICROENVIRONMENT (TME)',\n",
       "  22),\n",
       " ('POTENTIAL INFLUENCE OF INTEGRINS ON IMMUNE CELLS', 22),\n",
       " ('HEALTH BENEFITS OF FOOD ADDED WITH PROBIOTIC BACTERIA', 22),\n",
       " ('MOF-BASED ELECTROCHEMICAL SENSORS FOR DETECTION OF PHARMACEUTICALS', 22),\n",
       " ('APPENDIX B – HUMAN STUDIES CONSIDERED IN THE ASSESSMENT', 22),\n",
       " ('EXOSOME LOADING WITH TNAS', 22),\n",
       " ('MAIN EFFECTS POTENTIATED BY THE ENCAPSULATION OF PEPTIDES AND PROTEINS',\n",
       "  22),\n",
       " ('RESEARCH STATUS AND POTENTIAL APPLICATION FIELDS OF BIOMIMETIC ATTACHMENT EQUIPMENT INSPIRED BY AQUATIC ORGANISMS',\n",
       "  22),\n",
       " ('IMMUNOPATHOGENESIS OF LP', 22),\n",
       " ('DISCLAIMER', 21),\n",
       " ('NANOPARTICLES AND NANOVACCINE STRATEGY', 21),\n",
       " ('REVIEW FINDINGS', 21),\n",
       " ('IMMUNE RESPONSE TO AVIAN INFLUENZA VIRUSES', 21),\n",
       " ('FACTORS AFFECTING COVID-19 VACCINE UPTAKE IN DERMATOLOGY PATIENTS', 21),\n",
       " ('THE ROLE OF IGG4 ANTIBODIES INDUCED BY DIFFERENT VACCINES', 21),\n",
       " ('IMMUNOMODULATORY STRATEGIES ACTIVATING REGULATORY T CELLS FOR AD: IN VIVO ACTIVATION ',\n",
       "  21),\n",
       " ('ORGANIZATIONAL ASPECTS. GEMA DIFFUSION', 21),\n",
       " ('PEER REVIEW', 21),\n",
       " ('NANOSTRUCTURES FOR THE TREATMENT OF VIRAL RESPIRATORY INFECTIONS', 21),\n",
       " ('RATIONALE FOR AN INTS CONTROLLED HUMAN INFECTION MODEL', 21),\n",
       " ('IMMUNOPATHOGENESIS OF MPOX', 21),\n",
       " ('NANO-DERMOCOSMETICS', 21),\n",
       " ('FABRICATION OF MNS', 21),\n",
       " ('C3 ACTIVATION AND DOWNSTREAM EFFECTOR MOLECULES', 21),\n",
       " ('APPLICATIONS FOR HYBRID POLYMER-PROTEIN SYSTEMS IN CANCER THERAPY', 21),\n",
       " ('COMPONENTS RELATED TO COVID-19 TREATMENT', 21),\n",
       " ('CANCER PHARMACOTHERAPY', 21),\n",
       " ('IMPLEMENTATION', 21),\n",
       " ('THE GENITOURINARY MICROBIOME AND PROSTATIC CANCER', 21),\n",
       " ('CALCINEURIN INHIBITORS', 21),\n",
       " ('IMMUNOTHERAPY', 21),\n",
       " ('SELECTED NATURAL COMPOUNDS WITH IMMUNOMODULATING PROPERTIES', 21),\n",
       " ('EMPIRICAL ANALYSIS AND INTERPRETATION', 21),\n",
       " ('CHALLENGES IN THE PREPARATION OF POLYSACCHARIDE MICROPARTICLES', 21),\n",
       " ('THE GEOMETRY OF VIRAL\\xa0STRUCTURES', 21),\n",
       " ('PHAGE THERAPY', 21),\n",
       " ('INORGANIC NANOPARTICLES', 21),\n",
       " ('THE NEUROIMMUNOLOGY OF MULTIPLE SCLEROSIS', 21),\n",
       " ('PATHOGENESIS OF AMINOGLYCOSIDES—RELATED OTOTOXICITY', 21),\n",
       " ('STRATEGIES TO OPTIMIZE PEPTIDE STABILITY IN AQUEOUS FORMULATIONS', 21),\n",
       " ('THIRD-GENERATION ANTI-AMYLOID IMMUNOTHERAPIES IN ACTIVE CLINICAL DSEVELOPMENT',\n",
       "  21),\n",
       " ('POTENTIAL INTERVENTIONS', 21),\n",
       " ('ESSENTIAL OILS AND TERPENIC COMPOUNDS AGAINST AMITOCHONDRIATE PARASITES',\n",
       "  21),\n",
       " ('PASSIVE TARGETED DRUG DELIVERY SYSTEMS', 21),\n",
       " ('NATIVE PLANTS AND THEIR METABOLITES', 21),\n",
       " ('APPLICATION OF DIFFERENT BIODEGRADABLE OCULAR DRUG DELIVERY SYSTEMS ON OCULAR DISEASES',\n",
       "  21),\n",
       " ('ETHICS APPROVAL', 20),\n",
       " ('SHELLFISH ALLERGENS', 20),\n",
       " ('PERSONALIZED CANCER VACCINES', 20),\n",
       " ('ARTICLE INFORMATION', 20),\n",
       " ('DESIGN AND APPLICATION OF CTA-BASED TUMOR VACCINES', 20),\n",
       " ('PATHOPHYSIOLOGY', 20),\n",
       " ('FOREWORD', 20),\n",
       " ('IMMUNE RESPONSE TO SARS-COV-2', 20),\n",
       " ('WORKSHOP DISCUSSION OF PRACTICAL CONSIDERATIONS FOR DEVELOPMENT OF TB-CHIM',\n",
       "  20),\n",
       " ('PREVENTION OF INFECTIONS', 20),\n",
       " ('FOLLOW-UP', 20),\n",
       " ('THERAPIES AIMED AT TARGETING MCS IN CANCER', 20),\n",
       " ('GENE DELIVERY AND THERAPY IN SARS-COV-2 INFECTION', 20),\n",
       " ('DIAGNOSTIC MANAGEMENT', 20),\n",
       " ('SARS COV-2 SPIKE PROTEIN AND INTEGRIN BINDING MOTIFS', 20),\n",
       " ('ANTIBODIES TO WATCH IN 2023: NON-CANCER INDICATIONS', 20),\n",
       " ('HELMINTH INFECTIONS AND SARS-COV-2 INFECTION', 20),\n",
       " ('COCCIDIOIDOMYCOSIS', 20),\n",
       " ('UTILITY IN CANCER THERAPY', 20),\n",
       " ('SAFETY OF IL-23 P19 INHIBITORS', 20),\n",
       " ('INDUCTION OF THE TH2 RESPONSE', 20),\n",
       " ('CHALLENGES FOR BIO-INSPIRED NANOMATERIALS IN BIOMEDICAL APPLICATIONS', 20),\n",
       " ('APPLICATIONS OF HYDRODYNAMIC DELIVERY', 20),\n",
       " ('PHENOLIC COMPOUNDS', 20),\n",
       " ('RISK OR DETRIMENTAL EFFECTS OF CHILD-DOG INTERACTIONS FOR CHILDREN', 20),\n",
       " ('NANOMATERIALS', 20),\n",
       " ('CHITOSAN-BASED NANOPARTICLES', 20),\n",
       " ('EMERGING FIELDS IN NEUROIMMUNOLOGY', 20),\n",
       " ('CLASSICAL ‘AUTOIMMUNITY’ AND MITOCHONDRIA', 20),\n",
       " ('PERIPHERAL NERVOUS SYSTEM', 20),\n",
       " ('SUBVARIANTS', 20),\n",
       " ('SCIENTIFIC EXPERTS AND MEDIA', 20),\n",
       " ('SCIENTIFIC SUMMARY', 20),\n",
       " ('CHALLENGES OF EV APPLICATION AS DRUG DELIVERY CARRIERS', 20),\n",
       " ('PERICYTES IN THE REGULATION OF THE INNATE IMMUNE SYSTEM', 20),\n",
       " ('NOVEL BIODEGRADABLE OCULAR DRUG DELIVERY SYSTEMS', 20),\n",
       " ('KEY ISSUES FOR R&D OF BROADLY PROTECTIVE CORONAVIRUS VACCINES', 19),\n",
       " ('CASE', 19),\n",
       " ('PATHOGENESIS IN DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS', 19),\n",
       " ('DEVELOPMENT OF MNS DELIVERY OF VACCINES', 19),\n",
       " ('RECENT CLINICAL RESEARCH ADVANCES IN MRNA VACCINES IN VIRAL DISEASES', 19),\n",
       " ('MRNA VACCINES IN INFECTIOUS DISEASES', 19),\n",
       " ('MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS', 19),\n",
       " ('BACKGROUND/AIMS', 19),\n",
       " ('MOLECULAR INTERACTION ASSAYS MIAS', 19),\n",
       " ('TRIAL STATUS', 19),\n",
       " ('PH-RESPONSIVE VACCINE DELIVERY SYSTEM', 19),\n",
       " ('CURCUMIN AND INFECTIONS', 19),\n",
       " ('ENGINEERING DISCOVERY STRATEGIES FOR THERAPEUTIC MABS', 19),\n",
       " ('INNATE IMMUNE SYSTEMS AND SARS-COV-2 RESEARCH', 19),\n",
       " ('FOUR DIFFERENT CATEGORIES OF AUTOIMMUNE DISEASE', 19),\n",
       " ('MALIGNANCY ASSOCIATED WITH HIV', 19),\n",
       " ('IMMUNE RESPONSE OF MYCOBACTERIUM TUBERCULOSIS IN YOUNG HEALTHY INDIVIDUALS',\n",
       "  19),\n",
       " ('BIOMODULATORS AND IMMUNO-NUTRITION', 19),\n",
       " ('THEORETICAL FOUNDATION AND RESEARCH HYPOTHESES', 19),\n",
       " ('HELMINTH ALLERGENS', 19),\n",
       " ('CANNABINOIDS AND THEIR INFLUENCE ON THE TREATMENT OF COVID-19', 19),\n",
       " ('PRECLINICAL STUDIES', 19),\n",
       " ('CHALLENGES IN THE PHYSICOCHEMICAL CHARACTERIZATION AND DESIGNING OF NANO FORMULATION',\n",
       "  19),\n",
       " ('KEY PROGRAMMATIC ELEMENTS', 19),\n",
       " ('THE CAENORHABDITIS ELEGANS', 19),\n",
       " ('CYCLOPHOSPHAMIDE (CYC)', 19),\n",
       " ('BIOLOGICAL BARRIERS TO LIPID NANOPARTICLE DELIVERY', 19),\n",
       " ('THE RELATIONSHIP BETWEEN SIGA AND PULMONARY DISEASES', 19),\n",
       " ('PROTEIN REPLACEMENT THERAPY FOR MONOGENETIC DISORDERS', 19),\n",
       " ('ASTHMA MEDICATION', 19),\n",
       " ('VIRAL RESEARCH IN THE CONTEXT OF CANCER RESEARCH: AN ANALYSIS OF THE FEASIBILITY OF THE AMBATI ET AL. POSTULATE',\n",
       "  19),\n",
       " ('MN ARRAYS FOR DISEASE TREATMENT', 19),\n",
       " ('MANAGEMENT STRATEGIES', 19),\n",
       " ('IMMUNOBIOTICS AND POST-IMMUNOBIOTICS AS THE COMPONENTS OF FUNCTIONAL FOOD',\n",
       "  19),\n",
       " ('ANTIBIOTIC STEWARDSHIP IN THE HOSPITAL SETTING: STRATEGIES OF IMPLEMENTATION ',\n",
       "  19),\n",
       " ('VIRUSES AS DRUG DELIVERY SYSTEMS IN SELECTED CENTRAL NERVOUS SYSTEM DISEASES',\n",
       "  19),\n",
       " ('ANTIBODY-MEDIATED REJECTION', 19),\n",
       " ('ADVERSE EVENTS AFTER TNF-Α BLOCKER USE', 19),\n",
       " ('PATHOGENIC MECHANISMS BETWEEN THE RELATION OF INFECTIONS BY RESPIRATORY VIRUSES AND ASTHMA',\n",
       "  19),\n",
       " ('INTERACTION OF MDSCS WITH T CELLS', 19),\n",
       " ('CENTRAL AND PERIPHERAL NERVOUS SYSTEMS INVOLVEMENT', 19),\n",
       " ('AQUATIC-BASED COLLAGEN', 19),\n",
       " ('NANOTECHNOLOGIES AND LUNG CANCER DIAGNOSIS', 19),\n",
       " ('NEUROIMMUNOLOGICAL ASPECTS OF HEALTH AND DISEASES', 19),\n",
       " ('FUTURE RESEARCH DIRECTIONS', 19),\n",
       " ('MONOCLONAL ANTIBODIES', 19),\n",
       " ('NKT-LIKE CELLS: PROPERTIES', 19),\n",
       " ('CASE 5: POSTHERPETIC NEURALGIA (PHN) IN A CASE WITH BIPOLAR AFFECTIVE DISORDER',\n",
       "  19),\n",
       " ('THERAPEUTIC USE', 19),\n",
       " ('NANOPARTICLE-MEDIATED DRUG DELIVERY', 19),\n",
       " ('GROUP 4: DMS AS A CONSEQUENCE OF THE CRITICAL ILLNESS', 19),\n",
       " ('ET-1', 19),\n",
       " ('ABROCITINIB: EFFICACY AND SAFETY DATA', 19),\n",
       " ('SUSTAINABLE MATERIALS FOR DERMAL AND TRANSDERMAL PATCHES', 19),\n",
       " ('MICELLES IN TUMOR TARGETED DRUG RELEASE', 19),\n",
       " ('RODENT MODELS OF OBESITY', 19),\n",
       " ('SF HYDROGELS FOR SKIN AND WOUNDS', 19),\n",
       " ('MSNS: THERANOSTIC TOOL FOR INFLAMMATORY DISEASES', 19),\n",
       " ('BROADER PROGRESS SINCE GVIRF 2018', 18),\n",
       " ('RECOMMENDED VACCINES FOR THE ELDERLY', 18),\n",
       " ('NOTES', 18),\n",
       " ('COVID-19 VACCINES AND THEIR MNS DELIVERY', 18),\n",
       " ('AUTHORS’ CONTRIBUTIONS', 18),\n",
       " ('PATHOGENESIS AND CLINICAL FEATURES OF SEVERE DISEASE', 18),\n",
       " ('NANOMATERIAL DOSE JUSTIFICATION: A LENGTHY RUNWAY IN THE INVESTIGATION OF IMMUNOTOXICITY, EVEN WITHOUT PRE‐EXISTING CONDITIONS',\n",
       "  18),\n",
       " ('DNA AND GENOMICS: COWPOX VIRUS TO COWPOX VIRUSES', 18),\n",
       " ('STRENGTHS AND LIMITATIONS', 18),\n",
       " ('THERAPEUTICS OF COVID-19', 18),\n",
       " ('TREATMENTS WITH BIOMATERIALS BASED ON CHITOSAN', 18),\n",
       " ('CLINICAL PRESENTATION', 18),\n",
       " ('COMBINED IMMUNODEFICIENCY (CID), GENERALLY LESS PROFOUND THAN SCID', 18),\n",
       " ('MIRNA REGULATION OF ASTHMA PATHOGENESIS', 18),\n",
       " ('IMMUNE-MEDIATED CONDITIONS', 18),\n",
       " ('MRNA NPS: ADMINISTRATION ROUTES', 18),\n",
       " ('ASSESSMENT OF MNS', 18),\n",
       " ('NANOTECHNOLOGY IN PHARMACEUTICALS AND MEDICINE', 18),\n",
       " ('CHALLENGES IN THE CLINICAL TRANSLATION OF NANOMEDICINES', 18),\n",
       " ('LIPID-BASED NANOPARTICLES FOR SKIN CANCER THERAPY', 18),\n",
       " ('DAPSONE', 18),\n",
       " ('PROPOSED FRAMEWORK FOR ASTHMA HEALTHCARE\\xa0SYSTEM', 18),\n",
       " ('MANAGEMENT OF CGD', 18),\n",
       " ('PREVENTIVE ANTIVIRAL THERAPY', 18),\n",
       " ('NANOCARRIERS FOR DRUG DELIVERY IN CANINE OSA TREATMENTS', 18),\n",
       " ('STUDY 2—U.K. SURVEY', 18),\n",
       " ('UTILIZING BIOSURFACTANTS AS ADJUVANTS IN MEDICINE: DRUG DELIVERY SYSTEMS',\n",
       "  18),\n",
       " ('DYNAMICS OF VIRAL\\xa0STRUCTURES', 18),\n",
       " ('PLGA NANOMEDICINE PLATFORMS FOR DIFFERENT DISEASES', 18),\n",
       " ('BIOLOGY OF PROTEIN UPREGULATION', 18),\n",
       " ('TISSUE ENGINEERING AND REGENERATIVE MEDICINES', 18),\n",
       " ('THE BASICS OF NEUROIMMUNOLOGY', 18),\n",
       " ('PREVENTION OF AMINOGLYCOSIDE OTOTOXICITY', 18),\n",
       " ('MSCS AND MSC-DERIVED EXTRACELLULAR VESICLES (MSC-EVS)', 18),\n",
       " ('FUNCTIONAL ACTIVITIES OF STRICTININ', 18),\n",
       " ('CARBOPLATIN, THE SECOND-GENERATION PT AGENT', 18),\n",
       " ('TEST RESULTS', 18),\n",
       " ('PERIODONTAL MICROBIOTA', 18),\n",
       " ('MICROGLIA IN BEHAVIORAL AND NEUROPSYCHIATRIC DISORDERS', 18),\n",
       " ('BEHAVIORAL FACTORS ENHANCE CONVENTIONAL CANCER TREATMENTS', 18),\n",
       " ('EFFECTS AND CONSEQUENCES OF USING MEDICINAL INSECTS', 18),\n",
       " ('UNMET NEEDS AND RECOMMENDATIONS', 18),\n",
       " ('AVAILABILITY OF DATA AND MATERIALS', 17),\n",
       " ('THE ROLE OF VIRAL INFECTIONS INCLUDING COVID-19 IN CAUSING ACUTE URTICARIA',\n",
       "  17),\n",
       " ('DESCRIPTION OF STUDIES', 17),\n",
       " ('BACKGROUND & SUMMARY', 17),\n",
       " ('RECENT ADVANCEMENTS IN COVID-19 VACCINES', 17),\n",
       " ('COMPETING INTERESTS', 17),\n",
       " ('NASAL SPRAY FOR COVID-19 TREATMENT', 17),\n",
       " ('DUPILUMAB', 17),\n",
       " ('VIRAL RESPIRATORY DISEASE DIAGNOSTICS', 17),\n",
       " ('ECA-VAT-TAO GROUP MEMBERS AND THEIR AFFILIATED HEALTH CENTERS, VIGO HEALTH AREA, GALICIAN HEALTH SERVICE',\n",
       "  17),\n",
       " ('TRANSCRIPTIONAL REGULATION OF THE IGH GENE LOCUS, THE MASTER GENE FOR ALL ANTIBODY ISOTYPES',\n",
       "  17),\n",
       " ('PHYSICAL DEACTIVATION', 17),\n",
       " ('CLINICAL PRESENTATIONS', 17),\n",
       " ('BIOMIMETIC CELL-DERIVED NANOPARTICLES', 17),\n",
       " ('PRIMARY BRAIN TUMORS CLASSIFICATION AND FEATURES: FOCUS ON GB', 17),\n",
       " ('THE GALLERIA MELLONELLA MODEL', 17),\n",
       " ('AZATHIOPRINE (AZA)', 17),\n",
       " ('THERAPEUTIC APPLICATIONS OF LNP FORMULATIONS OF SIRNA', 17),\n",
       " ('MEDICINAL PLANTS AS IMMUNOMODULATORS', 17),\n",
       " ('VARIOUS NANO-FORMULATIONS: REVOLUTIONIZING DRUG DELIVERY', 17),\n",
       " ('INTRODUCTION TO MITOCHONDRIAL DISORDERS', 17),\n",
       " ('ALGORITHM AND AI-ASSISTED STRUCTURAL DESIGN', 17),\n",
       " ('THE HYGIENE HYPOTHESIS: YES, YOU MAY PICK YOUR NOSE AND EAT IT', 17),\n",
       " ('SPECIAL CONSIDERATIONS FOR BIOSAFETY AND BIOSECURITY', 17),\n",
       " ('STUDY 1—U.S. SURVEY', 17),\n",
       " ('STUDY 3—INTERNATIONAL SURVEY', 17),\n",
       " ('MANUFACTURING OF INFANT FORMULA', 17),\n",
       " ('CURRENT SOLUTIONS', 17),\n",
       " ('GUT DYSBIOSIS IN CHILDREN WITH ALL', 17),\n",
       " ('INFECTION SITES', 17),\n",
       " ('TREATMENT OF CHRONIC PAIN CONDITIONS USING ANTIMICROBIALS', 17),\n",
       " ('ISSUES RAISED BY OPPORTUNISTIC GNR', 17),\n",
       " ('PROPOSED TREATMENT GUIDE FOR ACO', 17),\n",
       " ('APPROVED ANTI-STAPHYLOCOCCAL ANTIBIOTICS SINCE 2010', 17),\n",
       " ('BORDERLINE REJECTION—TREATMENT', 17),\n",
       " ('INFLAMMATION IN OPHTHALMOLOGY DISEASES', 17),\n",
       " ('NANOPARTICLES', 17),\n",
       " ('SUSTAINABLE DEVELOPMENT GOALS AND SOLID WASTE IN THE CONTEXT OF THE COVID-19 PANDEMIC',\n",
       "  17),\n",
       " ('INTEGRATING MITOCHONDRIAL FUNCTION ACROSS ‘AUTOIMMUNITY’', 17),\n",
       " ('MOLECULAR BIOLOGICAL DETECTION', 17),\n",
       " ('FACTORS ENHANCING THE RISK OF AMINOGLYCOSIDE-INDUCED OTOTOXICITY', 17),\n",
       " ('INSTABILITY OF PEPTIDE AND THE POSSIBLE CAUSES OF DEGRADATION', 17),\n",
       " ('COMMUNITY-ACQUIRED PNEUMONIA', 17),\n",
       " ('CASE 2: MEMORY DYSFUNCTION WITH LANGUAGE AND BEHAVIORAL PROBLEMS', 17),\n",
       " ('THE ROLE OF MHLA-DR IN AP AND COVID-19', 17),\n",
       " ('JAK /STAT PATHWAY', 17),\n",
       " ('RELEASE OF ET-1', 17),\n",
       " ('COMBINING TWO PSS IN PDT AGAINST CANCER', 17),\n",
       " ('THYROID', 17),\n",
       " ('ANTIVIRAL ACTIONS OF QUERCETIN', 17),\n",
       " ('SYNTHESIS AND DISCUSSION', 17),\n",
       " ('GENETIC FORMS OF OBESITY', 17),\n",
       " ('BIOCHEMICAL PROFILING OF W. SOMNIFERA', 17),\n",
       " ('APPENDIX D – UNCERTAINTY ANALYSIS', 17),\n",
       " ('LIPOSOME-BASED CRISPR DELIVERY', 17),\n",
       " ('FUNCTION, CLUSTERING AND ENDOCYTOSIS OF GPI-APS', 17),\n",
       " ('PHYSICOCHEMICAL TARGETED DRUG DELIVERY SYSTEMS', 17),\n",
       " ('PRODUCTION OF THE INSECTS', 17),\n",
       " ('NON-SMOOTH STRUCTURAL MORPHOLOGIES AND ATTACHMENT MECHANISMS OF AQUATIC ORGANISMS',\n",
       "  17),\n",
       " ('OTHER CONSIDERATIONS FOR CLINICAL DIAGNOSIS AND MANAGEMENT', 16),\n",
       " ('FA IMMUNOTHERAPY TREATMENT', 16),\n",
       " ('MATERIALS AND EQUIPMENT', 16),\n",
       " ('EXPECTED OUTCOMES', 16),\n",
       " ('REGULATORY PATHWAYS AND FLEXIBILITY IN RESPONSE TO PANDEMICS', 16),\n",
       " ('MRNA VACCINES IN CANCERS', 16),\n",
       " ('IDENTIFIED TUMOR-ASSOCIATED ANTIGENS IN PEPTIDES VACCINE DEVELOPMENT FOR BREAST CANCER',\n",
       "  16),\n",
       " ('ONCOLOGY VACCINES', 16),\n",
       " ('AUTHOR STATEMENTS', 16),\n",
       " ('AVIAN INFLUENZA VACCINES', 16),\n",
       " ('VIRAL INFECTION MECHANISM', 16),\n",
       " ('TREATMENT MODALITIES', 16),\n",
       " ('MUCOSAL VACCINATION AGAINST C. DIFFICILE TOXINS', 16),\n",
       " ('ANALYTICAL CHARACTERIZATION OF ALUMINUM-ADSORBED ANTIGENS', 16),\n",
       " ('ANTIVIRAL DRUGS FOR SARS-COV-2', 16),\n",
       " ('CURRENT VIEWS ON SARS-COV-2-SPECIFIC T-CELL RESPONSES', 16),\n",
       " ('AI IMPLICATIONS IN IMMUNOLOGY, ALLERGOLOGY, AND COVID-19', 16),\n",
       " ('DIAGNOSTIC APPROACHES OF ZOONOTIC BRUCELLOSIS', 16),\n",
       " ('\\nMRNA FOR THERAPEUTIC APPLICATIONS', 16),\n",
       " ('NANOPARTICLES FOR MRNA DELIVERY', 16),\n",
       " ('THE EFFECT OF SECRETOME ON TREG/IL-17-PRODUCING TREG/TH17 CELL AXIS', 16),\n",
       " ('ASSESSMENT OF STUDIES INVESTIGATING IN VIVO EFFICACY OF AGR INHIBITORY DRUGS',\n",
       "  16),\n",
       " ('VIRUS, PATHOLOGY AND TRANSMISSION', 16),\n",
       " ('AGEING AND TUBERCULOSIS', 16),\n",
       " ('M1/M2 MACROPHAGES IN INFECTION', 16),\n",
       " ('PHASE I/II COMBINATION CLINICAL TRIAL OF ACV PLUS IBDV-R903/78 DRUG CANDIDATE FOR THE TREATMENT OF FACIAL HZ IN ELDERLY PATIENTS',\n",
       "  16),\n",
       " ('THE PROTEIN CORONA', 16),\n",
       " ('PEDIATRIC SLE AND COVID-19 VACCINES', 16),\n",
       " ('INTEGRATED MACHINE LEARNING-BASED PIPELINES FOR NEOANTIGEN PREDICTION', 16),\n",
       " ('ADVANCES IN THE IN SITU GENERATION OF CAR-T CELLS AND THEIR APPLICATION',\n",
       "  16),\n",
       " ('CASE REPORTS', 16),\n",
       " ('POLYSACCHARIDES', 16),\n",
       " ('MANAGEMENT OF LUNG INFECTIONS', 16),\n",
       " ('INFECTIOUS, POSTINFECTIOUS, AND POSTVACCINAL CAUSES OF CNS DEMYELINATION',\n",
       "  16),\n",
       " ('METABOLIC AND NUTRITIONAL CAUSES OF CNS DEMYELINATION', 16),\n",
       " ('ORAL ADMINISTRATION', 16),\n",
       " ('SURVEILLANCE', 16),\n",
       " ('THERAPEUTIC POTENTIAL OF TARGETING ALDHS', 16),\n",
       " ('IMPLANTS', 16),\n",
       " ('THERAPY AND PREVENTION OF LUNG INFECTIONS IN THE ELDERLY', 16),\n",
       " ('THE IMPACT OF IBD ON THE NEONATAL PERIOD', 16),\n",
       " ('DEVELOPMENTAL AND BIOLOGICAL FUNCTIONS OF DC SUBSETS', 16),\n",
       " ('PROPOSED AREAS TO STRENGTHEN FOR IMPROVED GLOBAL LUNG HEALTH', 16),\n",
       " ('CONCEPT OF NEXT-GENERATION PROBIOTICS (NGPS)', 16),\n",
       " ('CRS AND HUMAN MICROBIOME', 16),\n",
       " ('ROUTE OF ADMINISTRATION', 16),\n",
       " ('HYALURONIC ACID—THERAPEUTIC TARGET AND CHEMOTHERAPY ENHANCER', 16),\n",
       " ('PROBIOTICS AND HOST’S IMMUNE SYSTEM', 16),\n",
       " ('DNA-ORIGAMI-BASED APPROACHES AND THERAPEUTIC STRATEGIES FOR TARGETED DRUG DELIVERY',\n",
       "  16),\n",
       " ('COVID-19 AND CIRRHOSIS', 16),\n",
       " ('COVID-19 AND CHOLANGITIS', 16),\n",
       " ('COVID-19 AND NAFLD (NON-ALCOHOLIC FATTY LIVER DISEASE)', 16),\n",
       " ('T-CELL-MEDIATED REJECTION', 16),\n",
       " ('RESPIRATORY VIRUSES', 16),\n",
       " ('CHITOSAN-BASED NANOPARTICLE-BASED SYSTEMS FOR GERD TREATMENT', 16),\n",
       " ('PERSONAL PROTECTIVE EQUIPMENT (PPE)', 16),\n",
       " ('PROTEASE INHIBITORS', 16),\n",
       " ('LIPID-BASED NANOCARRIERS FOR THE CO-DELIVERY OF NATURAL COMPOUNDS AND OTHER THERAPEUTIC AGENTS',\n",
       "  16),\n",
       " ('ANTIDEPRESSANT ACTIVITY OF C. SATIVUS', 16),\n",
       " ('ROLES OF CAFS IN IMMUNITY', 16),\n",
       " ('MECHANISMS OF INTRATUMOR MICROBIOME IN MODULATING TUMOR INITIATION AND PROGRESSION',\n",
       "  16),\n",
       " ('CLINICAL INDICATIONS', 16),\n",
       " ('FUNCTIONAL RESPIRATORY IMAGING (FRI)', 16),\n",
       " ('THERAPEUTIC APPLICATIONS OF COLLAGEN-BASED BIOMATERIALS IN NEURAL TISSUE ENGINEERING',\n",
       "  16),\n",
       " ('FOCUS ON ABSORPTION OPTIMIZATION', 16),\n",
       " ('TOXICOLOGICAL MECHANISMS OF NPS', 16),\n",
       " ('EVALUATION MODELS OF NPS', 16),\n",
       " ('BACKGROUND AND DATA', 16),\n",
       " ('PATHOGENESIS AND PATHOPHYSIOLOGY', 15),\n",
       " ('PATENTS', 15),\n",
       " ('VACCINE RECOMMENDATIONS FOR 22Q11.2DEL AND OTHER DEFECTS IN THYMIC DEVELOPMENT',\n",
       "  15),\n",
       " ('FOOD ALLERGY', 15),\n",
       " ('SAFETY PROFILE OF MRNA VACCINES: EVIDENCE FROM CLINICAL TRIAL DATA AND POST-MARKET SURVEILLANCE',\n",
       "  15),\n",
       " ('PART 1 – UNDERLYING CONCEPTS', 15),\n",
       " ('NEW THERAPEUTIC APPROACHES', 15),\n",
       " ('AUTHOR STATEMENT', 15),\n",
       " ('NFIS DELIVERY OF DNA VACCINES FOR PANDEMIC VIRUSES', 15),\n",
       " ('IMMUNOLOGY OF SUBCUTANEOUS AND SUBLINGUAL IMMUNOTHERAPY', 15),\n",
       " ('ACKNOWLEDGEMENTS', 15),\n",
       " ('SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS', 15),\n",
       " (\"CHIKUNGUNYA AND O'NYONG-NYONG VIRUS\", 15),\n",
       " ('PROGRESS ON PLANT-BASED VACCINES FOR ALZHEIMER’S DISEASE', 15),\n",
       " ('CHARACTERISTICS OF THE UNUSUAL IGG4 ANTIBODY', 15),\n",
       " ('MODERN CPXV HOSTS AND OUTBREAKS', 15),\n",
       " ('COMBINATION OF HER-2/NEU-TARGETED THERAPY WITH IMMUNE CHECKPOINT BLOCKADE',\n",
       "  15),\n",
       " ('THE BRIEF LANDSCAPE OF LNP@MRNA IN CLINICAL GENE THERAPY', 15),\n",
       " ('INFLAMMATORY CELLS AND PHAGOCYTES', 15),\n",
       " ('SUGARS AS SARS-COV-2 SPIKE PROTEIN LIGANDS', 15),\n",
       " ('CHEMICAL STRUCTURES AND BIOLOGICAL PROPERTIES OF THE ANTI-ALLERGY COMPOUNDS LINKED WITH MARINE PLANTS, MARINE MICROORGANISMS, AND MARINE ANIMALS',\n",
       "  15),\n",
       " ('SARS-COV-2 VACCINE TRIAL', 15),\n",
       " ('HEV CLINICAL MANIFESTATIONS ', 15),\n",
       " ('DEVELOPMENT OF HEV VACCINE', 15),\n",
       " ('SPECTRUM OF INFECTIONS', 15),\n",
       " ('BIOFILMS ON MEDICAL DEVICES', 15),\n",
       " ('TOLL-LIKE RECEPTORS ', 15),\n",
       " ('MRNA NPS: ADVANCED NANODELIVERY SYSTEMS', 15),\n",
       " ('EPIDEMIOLOGICAL AND EXPERIMENTAL EVIDENCES FOR ADE', 15),\n",
       " ('RADX-UP TESTING CORE GUIDING STRATEGIES', 15),\n",
       " ('HISTORY OF COMPLEMENT INVOLVEMENT IN CORONAVIRUS INFECTIONS', 15),\n",
       " ('TIME HETEROGENEITY', 15),\n",
       " ('DESCRIPTION OF SOLANUM XANTHOCARPUM PLANT', 15),\n",
       " ('PROBIOTIC PROPERTIES AND MECHANISMS OF ACTION OF L. FERMENTUM CECT5716',\n",
       "  15),\n",
       " ('PROBIOTICS REDUCE COVID-19 SYMPTOMS OF THE GUT MUCOSA VIA THE GUT–LUNG AXIS',\n",
       "  15),\n",
       " ('PATHOPHYSIOLOGICAL FUNCTIONS OF FCRN', 15),\n",
       " ('BOVINE COLOSTRUM AND LACTOFERRIN AS SUPPORTIVE THERAPY IN STEROID TREATMENT AND PSYCHOPHYSICAL STRESS',\n",
       "  15),\n",
       " ('BIOACTIVITIES OF CHITOSAN', 15),\n",
       " ('PREIMPLANTATION STRESS AND DEVELOPMENT', 15),\n",
       " ('ART AND IMPRINTING DISORDERS (IDS)', 15),\n",
       " ('HOST PROTEINS AND IMMUNE RESPONSE AS ANTIVIRAL TARGETS OF SMALL MOLECULES',\n",
       "  15),\n",
       " ('PREPARATION OF POLYMER/NANOPARTICLES (NANO)COMPOSITES TO ATTEND PHARMACEUTICAL AND MEDICINAL APPLICATIONS',\n",
       "  15),\n",
       " ('IMMUNE CELL LANDSCAPE OF GIST', 15),\n",
       " ('HIV-RELATED FACTORS PROMOTING INFECTION AND IMMUNE EVASION', 15),\n",
       " ('ROLES OF ERΑ AND ERΒ IN CASTRATION-RESISTANT PROSTATE CANCER', 15),\n",
       " ('COMPARATIVE CLINICAL DISEASE', 15),\n",
       " ('EXOSOMES PARTICIPATE IN RESISTANCE OF TUMOR THERAPY', 15),\n",
       " ('HUMAN PROTEIN RECEPTORS FOR CORONAVIRUSES ARE PROTEASES', 15),\n",
       " ('CLINICAL TRIALS OF ANTI-SARS-COV-2 PRODRUGS FOR AGED POPULATIONS', 15),\n",
       " ('EOSINOPHILS IN THE TUMOR MICROENVIRONMENT', 15),\n",
       " ('CONCEPTS OF CNT-BASED ELECTROCHEMICAL BIOSENSOR', 15),\n",
       " ('APPLICATION OF RBC DELIVERY SYSTEMS', 15),\n",
       " ('TXNIP-DEPENDENT SIGNALING PATHWAYS IN CANCER', 15),\n",
       " ('INFECTIOUS DISEASES', 15),\n",
       " ('TARGETING IMMUNE AND INFLAMMATORY RESPONSES AND COAGULATION', 15),\n",
       " ('INTEGRATED MICROFLUIDIC‐BASED POCT DEVICES', 15),\n",
       " ('BIOSURFACTANTS AS BIOLOGICAL CONTROL AGENTS', 15),\n",
       " ('CONSIDERATIONS IN DEVELOPMENT OF INHALABLE NANOPARTICLE-BASED DRY POWDERS',\n",
       "  15),\n",
       " ('NON-INFECTIOUS INFLAMMATORY DISEASES INVOLVING THE ENDOCRINE SYSTEM', 15),\n",
       " ('ADAPTIVE RADIATION RESPONSE AND THE INVOLVEMENT OF MITOCHONDRIAL FUNCTIONS',\n",
       "  15),\n",
       " ('CHALLENGES AND FUTURE PERSPECTIVES OF DNA ORIGAMI NANOSTRUCTURES AS DELIVERY SYSTEM',\n",
       "  15),\n",
       " ('MOLECULAR INTERACTION OF MELITTIN (HONEYBEE VENOM) IN CANCER', 15),\n",
       " ('MANIFESTATIONS OF HIV/AIDS IN THE OROPHARYNGEAL MUCOSAL EPITHELIUM', 15),\n",
       " ('ANTIBIOTICS', 15),\n",
       " ('IMPLANT-ASSOCIATED INFECTION', 15),\n",
       " ('CURRENT ANTI-STAPHYLOCOCCAL ANTIBIOTICS: TARGETS AND RESISTANCE MECHANISMS',\n",
       "  15),\n",
       " ('OTHER PHARMACOLOGICAL ACTIVITIES OF NANOMATERIALS IN OPHTHALMOLOGY DISEASES',\n",
       "  15),\n",
       " ('TO 2000: TOXICOLOGICAL STUDIES ON HIGHLY EXPOSED POPULATIONS', 15),\n",
       " ('TOLERABILITY OF REMDESIVIR', 15),\n",
       " ('PLACE OF REMDESIVIR IN THE MANAGEMENT OF COVID-19', 15),\n",
       " ('鼻腔药物递送的影响因素', 15),\n",
       " ('FUNCTION OF PHAGOCYTOSIS CHECKPOINTS IN THE IMMUNE SYSTEM', 15),\n",
       " ('URINARY-TRACT INFECTIONS', 15),\n",
       " ('PROBIOTICS’ EFFECT IN PERIODONTAL AND PERI-IMPLANT DISEASES', 15),\n",
       " ('PROPOSED COMPUTER ARCHITECTURE', 15),\n",
       " ('CLINICAL TRIALS ON MICELLAR DRUG DELIVERY SYSTEMS', 15),\n",
       " ('HOW DOES THE INNATE IMMUNE RESPONSE CONTRIBUTE TO SEX DIFFERENCES IN DEPRESSION?',\n",
       "  15),\n",
       " ('MACROPHAGES M1/M2 POLARIZATION', 15),\n",
       " ('AN OVERVIEW OF THE BACTERIOCINS OF GRAM-POSITIVE BACTERIA', 15),\n",
       " ('PREPARATION OF SF GELS', 15),\n",
       " ('JANUS KINASE (JAK)\\xa0INHIBITORS', 15),\n",
       " ('AUTHOR CONTRIBUTION', 14),\n",
       " ('TIMELINES AND MILESTONES', 14),\n",
       " ('DEVELOPMENTAL STATUS OF VARIOUS VACCINES AGAINST COVID-19', 14),\n",
       " ('PART 2 - SEX AND GENDER DIFFERENCES IN DERMATOLOGICAL DISEASES', 14),\n",
       " ('DEVELOPMENT OF UNIVERSAL INFLUENZA VACCINE', 14),\n",
       " ('CHALLENGES AND PROSPECTS OF MNS DELIVERY OF VACCINES', 14),\n",
       " ('MRNA VACCINE OPTIMIZATION', 14),\n",
       " ('MRNA VACCINE DEVELOPMENT', 14),\n",
       " ('IMMUNOGENICITY', 14),\n",
       " ('PROBIOTICS AND AIT', 14),\n",
       " ('ACTIVE IMMUNIZATION', 14),\n",
       " ('STRUCTURE OF SARS-COV-2 SPIKE PROTEIN', 14),\n",
       " ('HEALTHCARE WORKER ATTITUDES TOWARD NON-COVID-19 AND COVID-19 VACCINES', 14),\n",
       " ('IMMUNE RESPONSE', 14),\n",
       " ('SURFACE-ANTIGEN MUCOSAL VACCINE', 14),\n",
       " ('MATERIALS AND PROCEDURES', 14),\n",
       " ('APPROVED ADJUVANTS AND THEIR INTRADERMAL REACTOGENICITY', 14),\n",
       " ('PHYSICAL ADJUVANTS FOR SAFE INTRADERMAL VACCINATION', 14),\n",
       " ('DISEASE OVERVIEW', 14),\n",
       " ('RECOMMENDATIONS', 14),\n",
       " ('DISSCUSSON', 14),\n",
       " ('CO-ADJUVANTS AND ADJUVANT FORMULATION', 14),\n",
       " ('LIPID NANOPARTICLES (LNPS)', 14),\n",
       " ('MEASURES', 14),\n",
       " ('CLINICAL PERSPECTIVE REGARDING TREG/IL-17-PRODUCING TREG/TH17 CELL AXIS MODULATION IN BC CANCER',\n",
       "  14),\n",
       " ('DIAGNOSTIC APPROACHES FOR H. PYLORI', 14),\n",
       " ('MICROENVIRONMENTAL AND SYSTEMIC CHANGES INDUCED BY DC VACCINE THERAPY', 14),\n",
       " ('THE CAUSATIVE AGENT – THE BOTULINUM NEUROTOXIN', 14),\n",
       " ('INDOOR AIRBORNE ALLERGENS', 14),\n",
       " ('BIOLOGICAL DRUGS', 14),\n",
       " ('AGING AND LYMPHOMA', 14),\n",
       " ('MRNA NPS: TARGETING AND ENDOCYTIC MECHANISMS', 14),\n",
       " ('HARNESSING THE UNIQUE FEATURES OF NK CELLS FOR A FUNCTIONAL CURE', 14),\n",
       " ('APPLICATIONS OF 3D-PRINTED MICRONEEDLES', 14),\n",
       " ('PROGNOSIS', 14),\n",
       " ('DESCRIPTION OF OCIMUM SANCTUM PLANT', 14),\n",
       " ('TLR4 AGONISTS BASED ON ΑGLCN(1↔1)ΑMAN AND ΒGLCN(1↔1)ΒGLCN SCAFFOLDS: TAILORED MODULATION OF TLR4-MEDIATED PRO-INFLAMMATORY SIGNALING BY ΑΑ-DLAMS AND ΒΒ-DLAMS',\n",
       "  14),\n",
       " ('NANOPARTICLES IN DRUG DELIVERY', 14),\n",
       " ('\\nRESULTS', 14),\n",
       " ('ARBOVIRUSES', 14),\n",
       " ('RADIOTHERAPY', 14),\n",
       " ('LACTOFERRIN AS SUPPORTIVE THERAPY IN ANTIBIOTIC TREATMENT', 14),\n",
       " ('GUT MICROBIOME, DIET, AND PROSTATE CANCER', 14),\n",
       " ('AUTOIMMUNE MYOCARDITIS AND DRUG-INDUCED MYOCARDITIS', 14),\n",
       " ('ANTIMALARIAL DRUGS', 14),\n",
       " ('PATHOGENS AND CGD-RELATED INFECTIOUS DISEASES', 14),\n",
       " ('NANOVEHICLES FOR LYMPHATIC DELIVERY', 14),\n",
       " ('LIPOSOMES AS NANOMEDICINE TOOLS', 14),\n",
       " ('EXTERNAL BEAM RADIATION THERAPY', 14),\n",
       " ('MANAGEMENT OF PATIENTS WITH HCC DURING COVID-19 PANDEMIC', 14),\n",
       " ('SM-FOCUSED DESIGN', 14),\n",
       " ('PROPHYLAXIS OF NOSOCOMIAL TRANSMISSION OF INFLUENZA', 14),\n",
       " ('OUTLOOK AND CHALLENGES', 14),\n",
       " ('ORTHODONTICS', 14),\n",
       " ('BIO-INSPIRED NANOMATERIALS: FROM CONCEPT TO REALIZATION', 14),\n",
       " ('CANINE OSA TREATMENTS', 14),\n",
       " ('HOW CAN SEX BIAS BE MINIMIZED IN BIOMEDICAL RESEARCH?', 14),\n",
       " ('THE GENOMIC AND IMMUNE LANDSCAPE OF PERIPHERAL T CELL LYMPHOMA', 14),\n",
       " ('EMERGING THERAPEUTIC STRATEGIES', 14),\n",
       " ('CAN THE FOCUS ON LONG COVID RESEARCH PROVIDE BENEFIT FOR ME/CFS PATIENTS?',\n",
       "  14),\n",
       " ('THE OPPOSITE EFFECT RELATED TO THE MOLECULAR WEIGHT OF HA', 14),\n",
       " ('STUDIES ON IMMUNOMODULATORY EFFECTS OF L-THEANINE IN VITRO AND IN ANIMAL MODELS',\n",
       "  14),\n",
       " ('POST-IMMUNOBIOTICS', 14),\n",
       " ('DISCUSSION AND IMPLICATIONS', 14),\n",
       " ('ADVANTAGES OF VIRUS-BASED BIOLOGICAL SYSTEMS AS NEXT-GENERATION CARRIERS FOR THE THERAPY OF CENTRAL NERVOUS SYSTEM DISEASES',\n",
       "  14),\n",
       " ('GENERAL PRINCIPLES OF NEUROPATHIC PAIN IN THE EMERGENCY SETTING', 14),\n",
       " ('CLINICAL DEVELOPMENT PROGRAM OF OFATUMUMAB IN MS AND THE 20 MG SUBCUTANEOUS DOSING REGIMEN',\n",
       "  14),\n",
       " ('PARTICIPANTS', 14),\n",
       " ('提高药物经鼻递送效率的策略', 14),\n",
       " ('MODULATION OF CAFS DURING TUMOR PROGRESSION', 14),\n",
       " ('DIAGNOSTIC MEDICINE', 14),\n",
       " ('IN MEDICAL GENETICS AND MOLECULAR PATHOLOGY', 14),\n",
       " ('A FRENCH EPISTEMIC COMMUNITY CHALLENGING BIOMEDICAL FRAMING', 14),\n",
       " ('EU-APPROVED RAPID TESTS', 14),\n",
       " ('PHARMACEUTICAL TREATMENTS', 14),\n",
       " ('C-DI-AMP RECEPTORS IN LAB', 14),\n",
       " ('HEALTH EFFECTS OF METABOLITES FROM PROBIOTIC BACTERIA', 14),\n",
       " ('VASCULAR CELL PATHWAYS', 14),\n",
       " ('BIOLOGICAL FUNCTIONS OF MICROGLIA', 14),\n",
       " ('CHITOSAN: PHYSICOCHEMICAL AND BIOLOGICAL PROPERTIES', 14),\n",
       " ('IRT AS AN ASSISTANCE TOOL IN INVASIVE AND SURGICAL PROCEDURES', 14),\n",
       " ('DIRECT (EXOGENOUS) STRATEGIES FOR TNA LOADING INTO EVS', 14),\n",
       " ('SF HYDROGELS FOR CARTILAGE', 14),\n",
       " ('DRUGS FOR COMMON DISEASES OR EXOGENOUS BIOMARKERS', 14),\n",
       " ('ACIDOPHILIC LACTIC ACID BACTERIA IN FOODS', 14),\n",
       " ('ENCAPSULATED PEPTIDES AND PROTEINS WITH EFFECTS ON OBESITY IN EXPERIMENTAL MODELS',\n",
       "  14),\n",
       " ('ZONULIN', 14),\n",
       " ('ANTIVIRAL TREATMENT', 14),\n",
       " ('GLYCYRRHIZIN AND RELATED TERPENOIDS AS EFFECTIVE ANTI-SARS-COV/SARS-COV-2 AGENTS: EXPERIMENTAL EVIDENCES',\n",
       "  14),\n",
       " ('DISEASE BURDEN', 14),\n",
       " ('LESSONS FROM COVID-19', 13),\n",
       " ('CONSENT FOR PUBLICATION', 13),\n",
       " ('POSSIBLE PATHOGENIC MECHANISMS OF VIRUS AND MAST CELL INTERACTIONS INVOLVED IN THE OCCURRENCE OF AU AND CU URTICARIA EXACERBATIONS WITH COVID-19 AND SARS-COV-2 VACCINATIONS',\n",
       "  13),\n",
       " ('IMMUNOLOGICAL LABORATORY ASSESSMENT', 13),\n",
       " ('DISCLOSURE STATEMENT', 13),\n",
       " ('VACCINE IMMUNE RESPONSES', 13),\n",
       " ('KEY SUMMARY POINTS', 13),\n",
       " ('RESOURCE AVAILABILITY', 13),\n",
       " ('FORMULATION ASPECTS OF MRNA-BASED VACCINES', 13),\n",
       " ('KEY POINTS', 13),\n",
       " ('COVID-19 MODELLING VERSUS REAL-WORLD DATA', 13),\n",
       " ('VENEZUELAN EQUINE ENCEPHALITIS VIRUS', 13),\n",
       " ('TYPES AND CHARACTERISTICS OF CANCER VACCINES', 13),\n",
       " ('CURRENT THERAPIES FOR SARS-COV-2 INFECTIONS IN NON-HOSPITALIZED PATIENTS',\n",
       "  13),\n",
       " ('APPLICATIONS OF BLPS IN BIOMEDICINE', 13),\n",
       " ('AI DISADVANTAGES AND LIMITATIONS IN MEDICINE', 13),\n",
       " ('LNP COMPOSITION AND PROPERTIES', 13),\n",
       " ('ALLERGENICITY FROM EGG PROTEINS', 13),\n",
       " ('CLINICAL CHARACTERISTICS OF HUMAN COCCIDIOIDOMYCOSIS LINKED TO INNATE SIGNALING DEFECTS',\n",
       "  13),\n",
       " ('INFLAMMATION: SARS-COV-2 INFECTION AS A CASE STUDY', 13),\n",
       " ('PROBLEMS IN CLINICAL APPLICATION OF LNP@MRNA', 13),\n",
       " ('RECENT STRATEGIES FOR THE CONTROL OF THE NIPAH AND HENDRA VIRUSES', 13),\n",
       " ('OBJECTIVES', 13),\n",
       " ('KEY CYTOKINE PATHWAYS IN KELOID FORMATION', 13),\n",
       " ('THERAPEUTICS AGAINST OMICRON', 13),\n",
       " ('ROLE OF TRAINED IMMUNITY AND ENDOTOXIN TOLERANCE IN INFLAMMATORY DISEASES',\n",
       "  13),\n",
       " ('IVT MRNA PURIFICATION', 13),\n",
       " ('SKIN CANCERS', 13),\n",
       " ('FUNCTIONAL MODIFICATIONS OF FERRITIN-BASED NANOPARTICLE DRUG DELIVERY SYSTEM',\n",
       "  13),\n",
       " ('DERMATOLOGICAL DISEASES DIRECTLY ASSOCIATED WITH BRACHYCEPHALY', 13),\n",
       " ('MONONUCLEAR PHAGOCYTE DIFFERENTIATION AND PLASTICITY', 13),\n",
       " ('CHEMICAL/BIOCHEMICAL DEACTIVATION', 13),\n",
       " ('INTERPLAY BETWEEN NK CELLS AND HIV-1', 13),\n",
       " ('IN VITRO CELL CULTURE SYSTEM TO PREDICT WHETHER CHEMICALS AND DRUGS MAY CAUSE AUTOIMMUNE RESPONSES IN ADVANCE',\n",
       "  13),\n",
       " ('VIRAL FACTORS', 13),\n",
       " ('ANTIVIRAL IMMUNITY AND SARS-COV-2 IMMUNOPATHOLOGY', 13),\n",
       " ('HSK THERAPEUTIC STRATEGIES AND CHALLENGES ', 13),\n",
       " ('ESSENTIAL OILS AS POTENTIAL ANTI-INFLUENZA AGENTS', 13),\n",
       " ('CHITIN BIOSYNTHESIS', 13),\n",
       " ('CHITIN BIOSYNTHESIS AS A TARGET FOR ANTIFUNGAL DRUGS', 13),\n",
       " ('BOVINE COLOSTRUM', 13),\n",
       " ('NANOCARRIERS OF ANTIVIRAL PEPTIDES AND ANTIVIRAL POLYSACCHARIDES', 13),\n",
       " ('DIRECT TARGETING OF EEV NON-STRUCTURAL PROTEINS (NSPS) WITH SMALL MOLECULES',\n",
       "  13),\n",
       " ('PROBIOTICS, PREBIOTICS, SYNBIOTICS, AND IMMUNITY', 13),\n",
       " ...]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "h1_list = [ p.split(' || ')[0].upper() for p in article_table['section_path'] ]\n",
    "\n",
    "h1_list = [ regex.sub(r'(STAR\\★|^\\d+.? )', '', p0) for p0 in h1_list ]  # remove 'STAR★' and section numbers\n",
    "\n",
    "# standardize on METHODS\n",
    "h1_list = [ 'METHODS' if 'METHOD' in p0 else p0 for p0 in h1_list ]\n",
    "\n",
    "# standardize on CONCLUSION\n",
    "h1_list = [ 'CONCLUSIONS' if 'CONCLUSION' in p0 else p0 for p0 in h1_list ]\n",
    "\n",
    "# Note that we do NOT do this for 'RESULTS AND DISCUSSION'; we want to keep these separate where possible.\n",
    "\n",
    "\n",
    "Counter(h1_list).most_common()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "c79c093d-c3ea-4f8f-8e35-6b2ca85b870a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['METHODS', 'RESULTS', 'DISCUSSION', 'INTRODUCTION', 'ABSTRACT']"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "targets = [t[0] for t in Counter(h1_list).most_common(5)]\n",
    "targets"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "d8d9c341-e3ca-4c7d-8aeb-d69d34166f99",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "135766"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "keep_rows = [ t in targets for t in h1_list ]\n",
    "\n",
    "flag_table = pd.DataFrame.from_dict( { t: [h==t for h in h1_list] for t in targets }, orient='columns')[keep_rows]\n",
    "len(flag_table)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "e5fe027a-f597-4534-bc6a-b85e3c9ee502",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "135766"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "X = [v for v in article_table['text_vector'][keep_rows].values]\n",
    "len(X)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "f1040b06-00f6-4ba4-97cc-35ee4f99abae",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fitting model for 'METHODS'\n",
      "Fitting model for 'RESULTS'\n",
      "Fitting model for 'DISCUSSION'\n",
      "Fitting model for 'INTRODUCTION'\n",
      "Fitting model for 'ABSTRACT'\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'METHODS': 0.9456549202393383,\n",
       " 'RESULTS': 0.853207639034571,\n",
       " 'DISCUSSION': 0.8503458472540654,\n",
       " 'INTRODUCTION': 0.8981477261941654,\n",
       " 'ABSTRACT': 0.8524947672673149}"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "MODEL_FILE = 'logreg_models.pkl'\n",
    "\n",
    "if os.path.exists(MODEL_FILE):\n",
    "    with open(MODEL_FILE, 'rb') as model_fh_in:\n",
    "        models = pickle.load(model_fh_in)\n",
    "else:\n",
    "    models = {}\n",
    "    for flag_col in flag_table.columns:\n",
    "        print(f\"Fitting model for '{flag_col}'\")\n",
    "        \n",
    "        clf = LogisticRegressionCV(cv=5, scoring='roc_auc', n_jobs=-1, max_iter=10000)\n",
    "        clf.fit(X, flag_table[flag_col])\n",
    "        models[flag_col] = clf\n",
    "\n",
    "    with open(MODEL_FILE, 'wb') as model_fh_out:\n",
    "        pickle.dump(models, model_fh_out)\n",
    "\n",
    "\n",
    "# Mean cross-validation AUC for each model\n",
    "{ t: np.mean([np.max(v) for v in mdl.scores_[True]]) for t, mdl in models.items() }\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "c5615843-b715-435d-8a2e-ac45124515d6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'METHODS': 0.9351648188172857,\n",
       " 'RESULTS': 0.8621212765640951,\n",
       " 'DISCUSSION': 0.8207674389096752,\n",
       " 'INTRODUCTION': 0.830585773685879,\n",
       " 'ABSTRACT': 0.8328962784008496,\n",
       " 'TITLE': 0.987145491259753,\n",
       " 'CONCLUSIONS': 0.8384550362602508}"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "{'METHODS': 0.9351648188172857,\n",
    " 'RESULTS': 0.8621212765640951,\n",
    " 'DISCUSSION': 0.8207674389096752,\n",
    " 'INTRODUCTION': 0.830585773685879,\n",
    " 'ABSTRACT': 0.8328962784008496,\n",
    " 'TITLE': 0.987145491259753,\n",
    " 'CONCLUSIONS': 0.8384550362602508}"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9d78d6cc-38d5-4ee4-968f-de900b271321",
   "metadata": {},
   "source": [
    "# Predict adverse events"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "60eba542-c7f5-4261-b704-a06381bd4de9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('Oversight and monitoring || Adverse event reporting and harms {22}', 24),\n",
       " ('Results || Adverse events', 17),\n",
       " ('Results ||  F- Adverse Effects (Non-infections and Non-malignancy)', 13),\n",
       " ('2. Methods || 2.7. Adverse Events, Diseases, etc.', 10),\n",
       " ('Design || Adverse events reporting and analysis', 10),\n",
       " ('Results || Population characteristics of SLE patients || Adverse events in SLE and comparisons with other subgroups',\n",
       "  9),\n",
       " ('3. Results || 3.1. Safety of the Immunotherapy  || 3.1.1. Adverse Reactions during Immunotherapy',\n",
       "  8),\n",
       " ('Materials and methods || Reported adverse events data', 8),\n",
       " ('Individual drug groups implicated in reactions || Drugs more rarely involved in preoperative, perioperative, and postoperative adverse reactions',\n",
       "  8),\n",
       " ('2. Methods || 2.3. Outcome Data || 2.3.2. Part II—Allergen-Specific Immunotherapy-Induced Adverse Events',\n",
       "  8),\n",
       " ('Imaging of immune-related adverse events || Thoracic toxicities', 8),\n",
       " ('Gut dysbiosis in children with ALL || Adverse early-life exposures can compromise gut microbiome-mediated immune priming',\n",
       "  7),\n",
       " ('2. Results || 2.5. Characteristics of the Adverse Events Related to Pruritus Using Hierarchical Clustering',\n",
       "  7),\n",
       " ('3. Results || 3.1. Adverse Reactions Induced by Vaccination', 6),\n",
       " ('4. Adverse Hematological Effects of COVID-19 Vaccination within the General Population || 4.4. Cardiovascular and Hematological Complications ',\n",
       "  6),\n",
       " ('3. Critical Analysis and Adverse Effects', 6),\n",
       " ('3. Results || 3.4. Monitoring, Prevention, and Treatment of Adverse Effects',\n",
       "  6),\n",
       " ('3. Results || 3.4. Adverse Reactions', 5),\n",
       " ('5. Adverse Effects Due to SARS-CoV-2 Vaccines', 5),\n",
       " ('3. Results and Discussion || 3.7. Safety and Adverse Events', 5),\n",
       " ('Results || First Vaccination Cycle (Two Doses) || Reported Adverse Events upon Two Vaccination Doses',\n",
       "  5),\n",
       " ('Results || Booster Dose || Reported Adverse Events upon Booster Vaccination Dose',\n",
       "  5),\n",
       " ('3. Results || 3.2. Evaluation of Adverse and Immunogenic Effects of the New Vaccine Ex Vivo',\n",
       "  5),\n",
       " ('Results || Safety || Solicited systemic adverse events', 5),\n",
       " ('3. Results || 3.3. Effectiveness of COVID-19 Vaccines in Reducing Adverse Maternal, Obstetric, and Neonatal Outcomes Associated with COVID-19',\n",
       "  5),\n",
       " ('Clinical relevance of immune-related adverse events', 5),\n",
       " ('Imaging of immune-related adverse events || Abdominal toxicities', 5),\n",
       " ('4. Adverse Events after TNF-α Blocker Use || 4.5. Development of Anti-Drug Antibodies (ADA)',\n",
       "  5),\n",
       " ('2. Results || 2.4. Characteristics of the Adverse Events Related to Pruritus Using Principal Component Analysis',\n",
       "  5),\n",
       " ('Tolerability of Remdesivir || Adverse Drug Reactions in the Real-World Setting',\n",
       "  5),\n",
       " ('DIAGNOSIS OF KIDNEY IMMUNE-RELATED ADVERSE EVENTS || Non-invasive diagnosis (potential biomarkers and imaging studies)',\n",
       "  5),\n",
       " ('6. Safety Profile of mRNA Vaccines: Evidence from Clinical Trial Data and Post-Market Surveillance || 6.2. Adverse Events of Special Interest',\n",
       "  4),\n",
       " ('Results || COVID-19 vaccine reported adverse effects || First and second dose adverse effects',\n",
       "  4),\n",
       " ('3. Recent Advancements in COVID-19 Vaccines || 3.3. Avoidance or Alleviation of Rare but Potentially Critical Adverse Reactions',\n",
       "  4),\n",
       " ('Methods || Type of Adverse Reactions', 4),\n",
       " ('Statistical methods || Oversight and monitoring || Adverse event reporting and harms {22}',\n",
       "  4),\n",
       " ('Results || Factors associated with adverse pregnancy outcomes', 4),\n",
       " ('2. Materials and Methods || 2.3. Immunization and Adverse Reactions', 4),\n",
       " ('6. Problems in Clinical Application of LNP@mRNA || 6.1. Immune-Related Adverse Effects',\n",
       "  4),\n",
       " ('Results || Inflammatory ocular adverse events', 4),\n",
       " ('Results || Safety || Unsolicited adverse events', 4),\n",
       " ('Results || Safety || Solicited local adverse events', 4),\n",
       " ('Results || Adverse event management and tolerability', 4),\n",
       " ('3. Results || 3.3. Part II Subcutaneous Allergen-Specific Immunotherapy-Induced Adverse Events in Equines',\n",
       "  4),\n",
       " ('3. Results || 3.7. Antifungal Treatment, Duration, and Adverse Events', 4),\n",
       " ('Imaging of immune-related adverse events || Central neurologic toxicity',\n",
       "  4),\n",
       " ('Imaging of immune-related adverse events || Endocrine toxicities', 4),\n",
       " ('Results || Primary outcomes || Adverse events of special interest', 4),\n",
       " ('4. Adverse Events after TNF-α Blocker Use || 4.4. Malignancy', 4),\n",
       " ('4. Adverse Events after TNF-α Blocker Use || 4.6. Other Adverse Events', 4),\n",
       " ('3. Results || 3.5. Treatment-Emergent Adverse Events (TEAEs)', 4),\n",
       " ('Scientific Summary || Adverse Events', 4),\n",
       " ('4. Adverse Reactions to Shellfish || 4.1. Immunological Adverse Reactions',\n",
       "  3),\n",
       " ('3. Results || 3.1. Total Case Series: PID and ADs || 3.1.3. Administered Vaccines and Adverse Effects',\n",
       "  3),\n",
       " ('Results || Prior exposure and sex are associated with the kinetics of the antibody response and adverse events induced by vaccination',\n",
       "  3),\n",
       " ('Results || A SD or RD regimen of GRAd-COV2 vaccine was well tolerated and induced mostly mild to moderate local and systemic adverse events of short duration',\n",
       "  3),\n",
       " ('Results || COVID-19 vaccine reported adverse effects || Adverse effects among males and females',\n",
       "  3),\n",
       " ('Results || COVID-19 vaccine reported adverse effects || Comparing the adverse effects of Pfizer, AstraZeneca, and Sinopharm vaccines',\n",
       "  3),\n",
       " ('3. Results || 3.7. Adverse Reactions and Events', 3),\n",
       " ('6. Reasons for Concern: Pharmacodynamic, Pharmacokinetic, and Pathophysiological || 6.8. Traditional COVID-19 Vaccines Not Contributing High Adverse Event Reports',\n",
       "  3),\n",
       " ('RESULTS || (ii) Nonimmediate adverse events.', 3),\n",
       " ('RESULTS || Adverse events', 3),\n",
       " ('Discussion || AESI and Serious Adverse Reactions', 3),\n",
       " ('3. Results || 3.2. Management of Adverse Reaction', 3),\n",
       " ('7. Adverse events', 3),\n",
       " ('7. Discussion || 7.1. How to Overcome Some Obstacles in the Development of mRNA Vaccines for Diminishing the Adverse Effects',\n",
       "  3),\n",
       " ('4. Adverse Hematological Effects of COVID-19 Vaccination within the General Population || 4.3. White Blood Cells',\n",
       "  3),\n",
       " ('Results || Second Booster Vaccine Dose (Fourth) || Reported Adverse Events upon Second Booster Vaccination Dose',\n",
       "  3),\n",
       " ('Results || Reported Adverse Events Sorted by Age', 3),\n",
       " ('Results || Description of adverse events following vaccination', 3),\n",
       " ('Results || Adverse reactions after inactivated vaccine against SARS-CoV-2',\n",
       "  3),\n",
       " ('RESULTS || Vaccination with heat-inactivated ZNF2oe cells in mice with preexisting asymptomatic infection causes no adverse effect and provides some protection.',\n",
       "  3),\n",
       " ('Statistical methods || Oversight and monitoring || Adverse event reporting and harms {22} || Sotrovimab arm',\n",
       "  3),\n",
       " ('Results || Subcategory analysis || Fear of adverse reactions', 3),\n",
       " ('3. Results || 3.2. Finding Significant Associations between Patient Medical History Factors and Post-Vaccination Adverse Reactions Using Statistical Analyses',\n",
       "  3),\n",
       " ('4. Summary of Polysorbate Safety || 4.1. Adverse Events || Hypersensitivity/Injection-Site Reactions',\n",
       "  3),\n",
       " ('Methods and analysis || Safety monitoring and adverse events', 3),\n",
       " ('Materials and methods || Study participants and definition of adverse drug events',\n",
       "  3),\n",
       " ('Results || Treatment-Emergent Adverse Events', 3),\n",
       " ('Methods || Outcomes and trial assessments || Adverse events', 3),\n",
       " ('RESULTS || Data on identified adverse effects || Systemic adverse effects || Lymphoma',\n",
       "  3),\n",
       " ('RESULTS || Data on identified adverse effects || Systemic adverse effects || Growth abnormalities',\n",
       "  3),\n",
       " ('Material and Methods || Adverse Drug Reactions (ADRs)', 3),\n",
       " ('Methods/design || Adverse events', 3),\n",
       " ('4. Adverse Events after TNF-α Blocker Use || 4.3. Drug-Induced Lupus', 3),\n",
       " ('Methods/Design || Adverse event reporting and risks ', 3),\n",
       " ('Methods and analysis || Adverse events and toxicity management', 3),\n",
       " ('TREATMENT || Pretreatment evaluation and monitoring || Other adverse events',\n",
       "  3),\n",
       " ('PATHOPHYSIOLOGY OF KIDNEY IMMUNE-RELATED ADVERSE EVENTS', 3),\n",
       " ('MANAGEMENT OF KIDNEY IMMUNE-RELATED ADVERSE EVENTS || ICI rechallenge considerations',\n",
       "  3),\n",
       " ('Study procedures || Adverse events', 3),\n",
       " ('4. Adverse Reactions to Shellfish || 4.2. Non-Immunological Adverse Reactions',\n",
       "  2),\n",
       " ('ADVERSE OUTCOME PATHWAYS AS AN EMERGING CONCEPT FOR IMMUNOTOXICOLOGY OF NANOMATERIALS',\n",
       "  2),\n",
       " ('ADVERSE OUTCOME PATHWAYS AS AN EMERGING CONCEPT FOR IMMUNOTOXICOLOGY OF NANOMATERIALS || \\nKE3: Dendritic cell maturation',\n",
       "  2),\n",
       " ('RESULTS || Adverse events identified in children and adolescents vaccinated with CoronaVac. (i) Immediate adverse events.',\n",
       "  2),\n",
       " ('2. The Challenges of COVID-19 Vaccines || 2.3. Rare but Potentially Critical Adverse Reactions Are Possible',\n",
       "  2),\n",
       " ('RESULTS || Vaccine safety and adverse reactions during observation', 2),\n",
       " ('Methods || Adverse events post-vaccination', 2),\n",
       " ('6. Safety Profiles and Potential Adverse Effects from AP', 2),\n",
       " ('4. Adverse Hematological Effects of COVID-19 Vaccination within the General Population || 4.1. Vaccine-Induced Immune Thrombocytopenia ',\n",
       "  2),\n",
       " ('Results || Safety || Incidence of adverse events', 2),\n",
       " ('3. Results || 3.6. Adverse Event Characteristics in Group A (5–11 Years)',\n",
       "  2),\n",
       " ('Results || Incidence of medically attended adverse events of interest by category',\n",
       "  2),\n",
       " ('Results || Vaccination status and adverse reactions', 2),\n",
       " ('Anticipation of potential adverse drug effects', 2),\n",
       " ('2. Materials and Methods || 2.4. Adverse Events', 2),\n",
       " ('Results || Adverse Events Following Immunisation (AEFIs) and Signal Detection',\n",
       "  2),\n",
       " ('Methods || Outcomes || Medical utilisation || Adverse outcomes', 2),\n",
       " ('Results || Safety || Adverse events summary', 2),\n",
       " ('Systematic review of human challenge studies using\\nM. tuberculosis\\n || Adverse event reporting',\n",
       "  2),\n",
       " ('Results || Eggshell membrane (ESM) administered as an adjuvant with rHBsAg did not adversely affect the experimental animals',\n",
       "  2),\n",
       " ('Results || Vaccine adverse events', 2),\n",
       " ('Result || Adverse effects noted after vaccination', 2),\n",
       " ('Methods/design || Safety and adverse effects', 2),\n",
       " ('Results || Systemic adverse reactions and laboratory finding changes', 2),\n",
       " ('Methods || COVID-2019 infection, vaccination, and adverse reactions', 2),\n",
       " ('Methods || Adverse event and symptom assessments', 2),\n",
       " ('Methods || Oversight and monitoring || Adverse event reporting and harms',\n",
       "  2),\n",
       " ('RESULTS || Data on identified adverse effects || Local adverse effects || Signs of skin thinning',\n",
       "  2),\n",
       " ('Results || Adverse events, severe COVID-19, & hospitalizations', 2),\n",
       " ('Results || Nelfinavir therapy observed no serious adverse events in COVID-19 patients',\n",
       "  2),\n",
       " ('3. Results and discussion || 3.8. Adverse events and clinical safety of FNC',\n",
       "  2),\n",
       " ('RESULTS || Treatment-emergent adverse events.', 2),\n",
       " ('Tolerability of Remdesivir || Adverse Events of Special Interest', 2),\n",
       " ('Results || Adverse events and satisfaction', 2),\n",
       " ('3. Results || 3.5. OTC-I Reveals No Adverse Effects via Acute Systemic Toxicity Study (Intravenous)',\n",
       "  2),\n",
       " ('4. Group 2: DMs Associated with Adverse Drug Reactions', 2),\n",
       " ('Safety || Serious adverse events', 2),\n",
       " ('Neurological immune-related adverse events || Description and pathophysiology',\n",
       "  2),\n",
       " ('Central nervous system neurological immune related adverse events || Meningitis and encephalitis || Symptoms',\n",
       "  2),\n",
       " ('Central nervous system neurological immune related adverse events || Meningitis and encephalitis || Grading and treatment',\n",
       "  2),\n",
       " ('Methods and analysis || Discontinuation and adverse event reporting', 2),\n",
       " ('DIAGNOSIS OF KIDNEY IMMUNE-RELATED ADVERSE EVENTS || Clinical features and time course of AIN',\n",
       "  2),\n",
       " ('MANAGEMENT OF KIDNEY IMMUNE-RELATED ADVERSE EVENTS || ATIN treatment', 2),\n",
       " ('MANAGEMENT OF KIDNEY IMMUNE-RELATED ADVERSE EVENTS || Impact of immune-related renal adverse events on cancer outcomes and CKD',\n",
       "  2),\n",
       " ('3. Adverse Events of ICIs || 3.1. Skin Reactions as irAEs || 3.1.1. Enhancement of Skin Inflammatory Disease',\n",
       "  2),\n",
       " ('3. Adverse Events of ICIs || 3.1. Skin Reactions as irAEs || 3.1.2. Common Cutaneous Disease Induced by ICIs as Cutaneous irAEs: Bullous Pemphigoid, Lichen Planus, Psoriasis',\n",
       "  2),\n",
       " ('4. Adverse Reactions to Shellfish', 1),\n",
       " ('Part 2 - Sex and Gender Differences in Dermatological Diseases || Cutaneous Adverse Drug Reactions',\n",
       "  1),\n",
       " ('Review findings || Adverse event following immunisation reporting', 1),\n",
       " ('2. Materials and Methods || 2.4. Demographic and Adverse Events Data Collection',\n",
       "  1),\n",
       " ('3. Results || 3.4. Adverse Reactions following Vaccination', 1),\n",
       " ('Results || Safety || Unsolicited Adverse Events', 1),\n",
       " ('Results || Adverse events and safety profile', 1),\n",
       " ('8. Limitations and Adverse Effects of Peptide Vaccines', 1),\n",
       " ('ADVERSE OUTCOME PATHWAYS AS AN EMERGING CONCEPT FOR IMMUNOTOXICOLOGY OF NANOMATERIALS || \\nKE1: Activation of the complement system',\n",
       "  1),\n",
       " ('ADVERSE OUTCOME PATHWAYS AS AN EMERGING CONCEPT FOR IMMUNOTOXICOLOGY OF NANOMATERIALS || \\nKE2: NLRP3 Inflammasome activation',\n",
       "  1),\n",
       " ('Results || Solicited Adverse Reactions', 1),\n",
       " ('Results || AESI and Serious Adverse Reactions', 1),\n",
       " ('Discussion || Solicited Adverse Reactions', 1),\n",
       " ('Discussion || Non-solicited Adverse Reactions', 1),\n",
       " ('3. Results || 3.2. Adverse Events', 1),\n",
       " ('METHODS || Vaccine safety and adverse reactions during observation', 1),\n",
       " ('2. Materials and Methods || 2.6. Adverse Events (AEs) Recording and Reporting',\n",
       "  1),\n",
       " ('3. Results || 3.3. Vaccine Adverse Events', 1),\n",
       " ('Results || Barriers || Overgeneralization of anecdotal adverse events and the lack of positive counter-narratives',\n",
       "  1),\n",
       " ('Results || Reactogenicity and adverse effects', 1),\n",
       " ('Methods || Adverse events post vaccination', 1),\n",
       " ('3. Results || 3.5. Adverse Events Following a Primary Series of COVID-19 Vaccination',\n",
       "  1),\n",
       " ('7. Adverse events || 1) Thrombosis with thrombocytopenia syndrome (TTS)',\n",
       "  1),\n",
       " ('7. Adverse events || 2) Myocarditis', 1),\n",
       " ('7. Adverse events || 3) Guillain-Barré syndrome', 1),\n",
       " ('Results || Characteristics of adverse events of SARS-CoV-2 mRNA vaccine',\n",
       "  1),\n",
       " ('Results || Comparison of adverse events including features of arthralgia after SARS-CoV-2 mRNA vaccination between RA patients and health care workers',\n",
       "  1),\n",
       " ('3. Results || 3.1. Adverse Effects after Vaccination', 1),\n",
       " ('2 Methods || 2.2 Definition of target adverse events', 1),\n",
       " ('Results || Topics Identified by the Topic Model || Topic 5: Vaccine Safety and Adverse Reactions',\n",
       "  1),\n",
       " ('4. Adverse Hematological Effects of COVID-19 Vaccination within the General Population || 4.2. Premenstrual and Menstrual Changes',\n",
       "  1),\n",
       " ('Materials and methods || Adverse events, safety, and toxicity evaluations',\n",
       "  1),\n",
       " ('Methods/design || Study outcomes || Serious adverse events (SAEs): hospitalization, death',\n",
       "  1),\n",
       " ('Methods/design || Study outcomes || Adverse events of special interest (AESI) resulting in hospitalization',\n",
       "  1),\n",
       " ('3. Results || 3.7. Adverse Event Characteristics in Group B (12–17 Years)',\n",
       "  1),\n",
       " ('Methods || Prespecified adverse events of interest', 1),\n",
       " ('MATERIALS AND METHODS || Adverse event and drug ID', 1),\n",
       " ('Materials and methods || Adverse reactions', 1),\n",
       " ('2. Materials and Methods || 2.4. Procedures || 2.4.3. Follow-Up of Adverse Events',\n",
       "  1),\n",
       " ('RESULTS || Adverse events following SARS‐CoV‐2 vaccination reporting practices',\n",
       "  1),\n",
       " ('Results || Adverse events following immunisation', 1),\n",
       " ('Methods || Infection with male S. mansoni cercariae || Adverse events', 1),\n",
       " ('Ethics and dissemination || Assessment of harm and adverse events', 1),\n",
       " ('Quality methods of included studies || Adverse events following immunization (AEFI) in included studies || Local AEFI',\n",
       "  1),\n",
       " ('Quality methods of included studies || Adverse events following immunization (AEFI) in included studies || Systemic AEFI',\n",
       "  1),\n",
       " ('Quality methods of included studies || Adverse events following immunization (AEFI) in included studies || Serious adverse events',\n",
       "  1),\n",
       " ('Quality methods of included studies || Adverse events following immunization (AEFI) in included studies || Health impact',\n",
       "  1),\n",
       " ('Quality methods of included studies || Adverse events following immunization (AEFI) in included studies || AESI and unsolicited AEFI by SOC',\n",
       "  1),\n",
       " ('Quality methods of included studies || Adverse events following immunization (AEFI) in included studies || Safety outcomes specific to clinical trials',\n",
       "  1),\n",
       " ('Results || Adverse outcomes', 1),\n",
       " ('Methods || Adverse events collection', 1),\n",
       " ('3. Results || 3.6. Adverse Events', 1),\n",
       " ('3. Results || 3.7. Serious Adverse Events', 1),\n",
       " ('Results || Adverse Events After Booster Dose of COVID-19 Vaccine', 1),\n",
       " ('3. Results || 3.3. Predictors of COVID-19 Booster Vaccine Hesitancy || 3.3.3. Adverse Events',\n",
       "  1),\n",
       " ('RESULTS || Adverse events and follow-up.', 1),\n",
       " ('Oversight and monitoring || Adverse event reporting and harms', 1),\n",
       " ('Statistical methods || Oversight and monitoring || Adverse event reporting and harms {22} || Niclosamide and ciclesonide arms',\n",
       "  1),\n",
       " ('Data collection and management || Adverse events', 1),\n",
       " ('Results || Vaccine-related adverse events and acute relapses', 1),\n",
       " ('Results || Timing and adverse effects of mRNA vaccination', 1),\n",
       " ('Methods || Hospital pneumonia surveillance and severe adverse events monitoring',\n",
       "  1),\n",
       " ('3. Results || 3.2. Adverse Reactions to Vaccination', 1),\n",
       " ('Materials and methods || Monitoring of adverse events (AEs)', 1),\n",
       " ('3. Results || 3.12. Safety and Adverse Events', 1),\n",
       " ('Results || Adverse event following immunization', 1),\n",
       " ('Results || Ingestion of EL-6 antibody with the blood meal adversely affects tick molting',\n",
       "  1),\n",
       " ('RESULTS || Adverse events after SARS-CoV-2 vaccination', 1),\n",
       " ('Methodology || Identification of CFs that impact COVID-19 directly || Evaluation of adverse mechanistic effects of eighty selected CFs',\n",
       "  1),\n",
       " ('2. Summary of Human Serum Albumin Safety || 2.1. Adverse Events', 1),\n",
       " ('4. Summary of Polysorbate Safety || 4.1. Adverse Events', 1),\n",
       " ('RESULTS || Adverse Events', 1),\n",
       " ('Results || Safety || Overall adverse events/reactions', 1),\n",
       " ('Results || DAT compensates for the adverse effects that result from antibiotic treatment during anti-CTLA-4 immunotherapy',\n",
       "  1),\n",
       " ('Results || DAT supplementation does not aggravate immune-related adverse events during anti-CTLA-4 treatment',\n",
       "  1),\n",
       " ('Methods || Adverse event reporting', 1),\n",
       " ('Materials and methods || Adverse reaction monitor', 1),\n",
       " ('Results || Adverse reactions after each dose of vaccination', 1),\n",
       " ('Results || Relationship between sleep quality before vaccination and the chance of adverse reactions after vaccination',\n",
       "  1),\n",
       " ('Results || The role of the sleep quality change between before and after vaccination in the chance of adverse reactions',\n",
       "  1),\n",
       " ('Results || Serious adverse events after a first dose of vaccine', 1),\n",
       " ('Results || Adverse effects reported in the vaccinated group', 1),\n",
       " ('Results || Study Drug Adherence and Serious Adverse Events', 1),\n",
       " ('Model and results || Other adverse effects of humoral memory', 1),\n",
       " ('2. Antimalarial Drugs || 2.2. Safety || 2.2.1. Gastrointestinal Adverse Reactions',\n",
       "  1),\n",
       " ('2. Antimalarial Drugs || 2.2. Safety || 2.2.2. Dermatologic Adverse Events',\n",
       "  1),\n",
       " ('2. Antimalarial Drugs || 2.2. Safety || 2.2.5. Neuromuscular Adverse Events',\n",
       "  1),\n",
       " ('2. Methods || 2.1. Eligibility Criteria || 2.1.2. Part II—Allergen-Specific Immunotherapy-Induced Adverse Events',\n",
       "  1),\n",
       " ('Results || Effects of intervention || Adverse events leading to death', 1),\n",
       " ('Results || Effects of intervention || Adverse events of special interest',\n",
       "  1),\n",
       " ('3 Results || 3.5 Study drug-related adverse and SAEs', 1),\n",
       " ('Results || Safety and adverse events', 1),\n",
       " ('Results || Serious adverse effect', 1),\n",
       " ('Imaging of immune-related adverse events || Neuromuscular toxicity', 1),\n",
       " ('Results || Adverse drug reactions', 1),\n",
       " ('Results || Primary outcomes || Treatment-emergent adverse events', 1),\n",
       " ('3. Results || 3.3. Adverse Events', 1),\n",
       " ('Methods || Adverse Effects', 1),\n",
       " ('RESULTS || Adverse effects identified', 1),\n",
       " ('RESULTS || Adverse effects for which no studies were identified', 1),\n",
       " ('RESULTS || Data on identified adverse effects', 1),\n",
       " ('RESULTS || Data on identified adverse effects || Systemic adverse effects || Type 2 diabetes',\n",
       "  1),\n",
       " ('RESULTS || Data on identified adverse effects || Systemic adverse effects || Reduction in BMD',\n",
       "  1),\n",
       " ('RESULTS || Data on identified adverse effects || Systemic adverse effects || Clinical signs of adrenal insufficiency',\n",
       "  1),\n",
       " ('RESULTS || Data on identified adverse effects || Systemic adverse effects || Other adverse effects (non‐skin infections, impaired vaccine response and non‐lymphoma malignancies)',\n",
       "  1),\n",
       " ('Methods and analysis || Data collection, management and analysis || Registration of adverse events',\n",
       "  1),\n",
       " ('Results || Non-intubated group || Adverse events', 1),\n",
       " ('Methods/design || Adverse events || Protocol amendments', 1),\n",
       " ('4. Adverse Events after TNF-α Blocker Use', 1),\n",
       " ('4. Adverse Events after TNF-α Blocker Use || 4.1. Infections', 1),\n",
       " ('4. Adverse Events after TNF-α Blocker Use || 4.2. Demyelinating Disorders',\n",
       "  1),\n",
       " ('Results || Adverse events related to c4G12 treatment', 1),\n",
       " ('4. Materials and Methods || 4.3. Definitions of Pruritus-Related Adverse Events',\n",
       "  1),\n",
       " ('Results || Primary outcomes: Serious adverse events', 1),\n",
       " ('2. Results || 2.3. EA Shows No Adverse Effects on Mucosal Innate Immunity',\n",
       "  1),\n",
       " ('Online Methods || Human studies || Adverse Event:', 1),\n",
       " ('Online Methods || Human studies || Recording Adverse Events:', 1),\n",
       " ('Online Methods || Human studies || Life-Threatening Adverse Event/Life-Threatening Suspected Adverse Reaction:',\n",
       "  1),\n",
       " ('Online Methods || Human studies || Serious Adverse Event/Serious Suspected Adverse Reaction:',\n",
       "  1),\n",
       " ('Online Methods || Human studies || Unexpected Adverse Event/Unexpected Suspected Adverse Reaction:',\n",
       "  1),\n",
       " ('Online Methods || Human studies || Grading of Adverse Events: The severity of AEs was assessed as follows:',\n",
       "  1),\n",
       " ('3. Results || 3.9. Adverse Events', 1),\n",
       " ('3 Results || 3.2 Outcomes || 3.2.3 Safety assessment || 3.2.3.1 Adverse events',\n",
       "  1),\n",
       " ('3. Results || 3.4. Adverse Events', 1),\n",
       " ('Results || Adverse event profile', 1),\n",
       " ('Discussion and safety review || Repeated dose oral toxicity || Sub-Chronic || No-observed adverse effect levels (NOAEL)',\n",
       "  1),\n",
       " ('Methods: participants, interventions and outcomes || Oversight and monitoring || Adverse event reporting and harms',\n",
       "  1),\n",
       " ('Neurological immune-related adverse events || Epidemiology', 1),\n",
       " ('Neurological immune-related adverse events || Grading and treatment', 1),\n",
       " ('Neurological immune-related adverse events || Prognosis', 1),\n",
       " ('Central nervous system neurological immune related adverse events || Meningitis and encephalitis || Description and pathophysiology',\n",
       "  1),\n",
       " ('Central nervous system neurological immune related adverse events || Meningitis and encephalitis || Epidemiology',\n",
       "  1),\n",
       " ('Central nervous system neurological immune related adverse events || Meningitis and encephalitis || Prognosis',\n",
       "  1),\n",
       " ('Central nervous system neurological immune related adverse events || Encephalitis variants || Limbic encephalitis',\n",
       "  1),\n",
       " ('Central nervous system neurological immune related adverse events || Encephalitis variants || Cerebellitis and rhombencephalitis',\n",
       "  1),\n",
       " ('Central nervous system neurological immune related adverse events || Encephalitis variants || Reversible posterior leukoencephalopathy syndrome',\n",
       "  1),\n",
       " ('Results || Adverse effects', 1),\n",
       " ('Evidence for developmental origins of disease || Maternal health, adverse birth outcomes, and poor health trajectory',\n",
       "  1),\n",
       " ('3. Results || 3.1. Study selection || 3.3. Self-medication practice during COVID-19 pandemic || 3.3.8. Adverse drug reactions',\n",
       "  1),\n",
       " ('Methods: Participants, interventions, and outcomes || Oversight and monitoring || Adverse event reporting and harms',\n",
       "  1),\n",
       " ('Results || Supplementary analyses || Adverse events', 1),\n",
       " ('INCIDENCE AND KNOWN RISK FACTORS FOR KIDNEY IMMUNE-RELATED ADVERSE EVENTS',\n",
       "  1),\n",
       " ('DIAGNOSIS OF KIDNEY IMMUNE-RELATED ADVERSE EVENTS || Types of kidney lesions',\n",
       "  1),\n",
       " ('DIAGNOSIS OF KIDNEY IMMUNE-RELATED ADVERSE EVENTS || Kidney biopsy indications',\n",
       "  1),\n",
       " ('MANAGEMENT OF KIDNEY IMMUNE-RELATED ADVERSE EVENTS || Treatment of glomerular lesions associated with ICI',\n",
       "  1),\n",
       " ('Results || Clinical outcome and adverse events', 1),\n",
       " ('3. Results || 3.1. Echinacea || 3.1.2. Adverse Events', 1),\n",
       " ('3. Results || 3.2. Elderberry || 3.2.2. Adverse Events', 1),\n",
       " ('3. Results || 3.3. Garlic || 3.3.2. Adverse Events', 1),\n",
       " ('3. Results || 3.4. Vitamin A || 3.4.2. Adverse Events', 1),\n",
       " ('3. Results || 3.5. Vitamin C || 3.5.2. Adverse Events', 1),\n",
       " ('3. Results || 3.6. Vitamin D || 3.6.2. Adverse Events', 1),\n",
       " ('3. Results || 3.7. Vitamin E || 3.7.2. Adverse Events', 1),\n",
       " ('3. Results || 3.8. Zinc || 3.8.2. Adverse Events', 1),\n",
       " ('Methods and analysis || Adverse events', 1),\n",
       " ('Methods and analysis || Outcome assessment || Safety assessment and adverse events reporting',\n",
       "  1),\n",
       " ('3. Results || 3.5. Adverse events', 1),\n",
       " ('3. Adverse Events of ICIs || 3.1. Skin Reactions as irAEs', 1),\n",
       " ('3. Adverse Events of ICIs || 3.2. Systemic irAEs Caused by ICIs', 1),\n",
       " ('Results || Tolerability and adverse events', 1),\n",
       " ('Results || Adverse events (AEs)', 1),\n",
       " ('Results || Adverse event', 1),\n",
       " ('Results || Adverse events (AEs), and complications', 1),\n",
       " ('Results || Violations Related to Adverse Events Reporting', 1),\n",
       " ('Discussion || Violations Related to Adverse Event Reporting', 1)]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Counter([ p for p in article_table['section_path'] if regex.search('adverse', p, regex.IGNORECASE)]).most_common()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "7a0dce78-aaf9-49d2-9426-f6363fb80d6b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fitting model for pattern 'adverse'\n",
      "adverse 0.9105883095030529\n",
      "Fitting model for pattern 'population'\n",
      "population 0.8373245630511568\n",
      "Fitting model for pattern 'treatment'\n",
      "treatment 0.8446813142663533\n"
     ]
    }
   ],
   "source": [
    "patterns = ['adverse', 'population', 'treatment']\n",
    "\n",
    "get_mean_xval_score_for_binary_classifier = lambda clf: np.mean([np.max(v) for v in clf.scores_[True]])\n",
    "\n",
    "\n",
    "pattern_models = {}\n",
    "X_all = [v for v in article_table['text_vector'].values]\n",
    "for pat in patterns:\n",
    "    print(f\"Fitting model for pattern '{pat}'\")\n",
    "    \n",
    "    y_pat = [ 1 if regex.search(pat, p, regex.IGNORECASE) else 0 for p in article_table['section_path'] ]\n",
    "    \n",
    "    clf = LogisticRegressionCV(cv=5, scoring='roc_auc', n_jobs=-1, max_iter=10000)\n",
    "    clf.fit(X_pat, y_pat)\n",
    "    print(pat, get_mean_xval_score_for_binary_classifier(clf))\n",
    "    pattern_models[pat] = clf\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "340b62ec-cc29-4030-8569-df6930ff15a8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>adverse</th>\n",
       "      <th>population</th>\n",
       "      <th>treatment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195690</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195691</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195692</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195693</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195694</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>195695 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        adverse  population  treatment\n",
       "0             0           0          0\n",
       "1             0           0          0\n",
       "2             0           0          0\n",
       "3             0           0          0\n",
       "4             0           0          0\n",
       "...         ...         ...        ...\n",
       "195690        0           0          0\n",
       "195691        0           0          0\n",
       "195692        0           0          0\n",
       "195693        0           0          0\n",
       "195694        0           0          0\n",
       "\n",
       "[195695 rows x 3 columns]"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pattern_flag_dict = {}\n",
    "\n",
    "# Note that here we are looking for the pattern only in the section path, not in the text itself.\n",
    "for pat in patterns:\n",
    "    y_pat = [ 1 if regex.search(pat, p, regex.IGNORECASE) else 0 for p in article_table['section_path'] ]\n",
    "    pattern_flag_dict[pat] = y_pat\n",
    "\n",
    "pattern_flags = pd.DataFrame.from_dict(pattern_flag_dict, orient='columns')\n",
    "pattern_flags"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "a8a98b97-782e-47b7-ab4c-2c0a589e1557",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'adverse': 0.9105883095030529,\n",
       " 'population': 0.8373245630511568,\n",
       " 'treatment': 0.8446813142663533}"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "{ t: get_mean_xval_score_for_binary_classifier(mdl) for t, mdl in pattern_models.items() }"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "18a26942-177f-492d-9adf-ebeb72241f37",
   "metadata": {},
   "source": [
    "# Score all cases with all models\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "c1f793e5-018f-48bc-8bb0-0feab081a79d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>METHODS</th>\n",
       "      <th>RESULTS</th>\n",
       "      <th>DISCUSSION</th>\n",
       "      <th>INTRODUCTION</th>\n",
       "      <th>ABSTRACT</th>\n",
       "      <th>adverse</th>\n",
       "      <th>population</th>\n",
       "      <th>treatment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.392729</td>\n",
       "      <td>0.013144</td>\n",
       "      <td>0.106685</td>\n",
       "      <td>0.164764</td>\n",
       "      <td>0.001212</td>\n",
       "      <td>0.001405</td>\n",
       "      <td>0.004748</td>\n",
       "      <td>0.001212</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.467891</td>\n",
       "      <td>0.090845</td>\n",
       "      <td>0.154400</td>\n",
       "      <td>0.037906</td>\n",
       "      <td>0.002511</td>\n",
       "      <td>0.003029</td>\n",
       "      <td>0.003403</td>\n",
       "      <td>0.002511</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.008582</td>\n",
       "      <td>0.248929</td>\n",
       "      <td>0.385940</td>\n",
       "      <td>0.192315</td>\n",
       "      <td>0.002386</td>\n",
       "      <td>0.003355</td>\n",
       "      <td>0.001390</td>\n",
       "      <td>0.002386</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.466348</td>\n",
       "      <td>0.035729</td>\n",
       "      <td>0.327583</td>\n",
       "      <td>0.095015</td>\n",
       "      <td>0.002845</td>\n",
       "      <td>0.003805</td>\n",
       "      <td>0.009403</td>\n",
       "      <td>0.002845</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.571138</td>\n",
       "      <td>0.023829</td>\n",
       "      <td>0.470320</td>\n",
       "      <td>0.054129</td>\n",
       "      <td>0.003004</td>\n",
       "      <td>0.001542</td>\n",
       "      <td>0.003134</td>\n",
       "      <td>0.003004</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195690</th>\n",
       "      <td>0.008612</td>\n",
       "      <td>0.025737</td>\n",
       "      <td>0.279532</td>\n",
       "      <td>0.604809</td>\n",
       "      <td>0.040869</td>\n",
       "      <td>0.000782</td>\n",
       "      <td>0.002373</td>\n",
       "      <td>0.040869</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195691</th>\n",
       "      <td>0.002589</td>\n",
       "      <td>0.139488</td>\n",
       "      <td>0.668194</td>\n",
       "      <td>0.223457</td>\n",
       "      <td>0.024458</td>\n",
       "      <td>0.000778</td>\n",
       "      <td>0.004517</td>\n",
       "      <td>0.024458</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195692</th>\n",
       "      <td>0.000404</td>\n",
       "      <td>0.140186</td>\n",
       "      <td>0.455792</td>\n",
       "      <td>0.193495</td>\n",
       "      <td>0.006777</td>\n",
       "      <td>0.000665</td>\n",
       "      <td>0.008123</td>\n",
       "      <td>0.006777</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195693</th>\n",
       "      <td>0.000140</td>\n",
       "      <td>0.411427</td>\n",
       "      <td>0.523791</td>\n",
       "      <td>0.288862</td>\n",
       "      <td>0.009735</td>\n",
       "      <td>0.001574</td>\n",
       "      <td>0.006667</td>\n",
       "      <td>0.009735</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195694</th>\n",
       "      <td>0.005008</td>\n",
       "      <td>0.035006</td>\n",
       "      <td>0.463674</td>\n",
       "      <td>0.317586</td>\n",
       "      <td>0.054359</td>\n",
       "      <td>0.000834</td>\n",
       "      <td>0.003967</td>\n",
       "      <td>0.054359</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>195695 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         METHODS   RESULTS  DISCUSSION  INTRODUCTION  ABSTRACT   adverse  \\\n",
       "0       0.392729  0.013144    0.106685      0.164764  0.001212  0.001405   \n",
       "1       0.467891  0.090845    0.154400      0.037906  0.002511  0.003029   \n",
       "2       0.008582  0.248929    0.385940      0.192315  0.002386  0.003355   \n",
       "3       0.466348  0.035729    0.327583      0.095015  0.002845  0.003805   \n",
       "4       0.571138  0.023829    0.470320      0.054129  0.003004  0.001542   \n",
       "...          ...       ...         ...           ...       ...       ...   \n",
       "195690  0.008612  0.025737    0.279532      0.604809  0.040869  0.000782   \n",
       "195691  0.002589  0.139488    0.668194      0.223457  0.024458  0.000778   \n",
       "195692  0.000404  0.140186    0.455792      0.193495  0.006777  0.000665   \n",
       "195693  0.000140  0.411427    0.523791      0.288862  0.009735  0.001574   \n",
       "195694  0.005008  0.035006    0.463674      0.317586  0.054359  0.000834   \n",
       "\n",
       "        population  treatment  \n",
       "0         0.004748   0.001212  \n",
       "1         0.003403   0.002511  \n",
       "2         0.001390   0.002386  \n",
       "3         0.009403   0.002845  \n",
       "4         0.003134   0.003004  \n",
       "...            ...        ...  \n",
       "195690    0.002373   0.040869  \n",
       "195691    0.004517   0.024458  \n",
       "195692    0.008123   0.006777  \n",
       "195693    0.006667   0.009735  \n",
       "195694    0.003967   0.054359  \n",
       "\n",
       "[195695 rows x 8 columns]"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "X_all = [v for v in article_table['text_vector'].values]\n",
    "model_scores = {}\n",
    "for target, model in models.items():\n",
    "    model_scores[target] = model.predict_proba(X_all)[:,1]\n",
    "\n",
    "for pattern, model in pattern_models.items():\n",
    "    model_scores[pattern] = model.predict_proba(X_all)[:,1]\n",
    "\n",
    "scores_df = pd.DataFrame.from_dict(model_scores, orient='columns')\n",
    "\n",
    "scores_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "a8c3ce6e-e07d-4f92-be57-1945ef46dc6e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<seaborn.matrix.ClusterGrid at 0x2a893bf5510>"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x1000 with 4 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import seaborn as sns\n",
    "\n",
    "sns.clustermap(scores_df.corr())"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "704446fa-7b4e-4c7c-93d3-1f4d3c43428a",
   "metadata": {},
   "source": [
    "# To do:\n",
    "* use models to score cases that do not have any of the standard labels. Which of the non-standard labels correlate with scores from the standard labels? Discussion vs. Conclusion?\n",
    "* How are the scores for each model distributed for each label? Start by computing model means for each flag value.\n",
    "* Use a decision tree to classify paragraphs using a set of general model scores as features; semi-interpretability.\n",
    "\n",
    "* predict semantic model scores from tags with DT round robin => combine soft labels to get something predictable (nonlinear conditional combinations)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "bab1f656-9de1-49cd-bb5f-1492ab3b7bf3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Counter({2: 68442, 0: 64091, 1: 63162})"
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def get_bucket(id, num_buckets=3):\n",
    "    import hashlib\n",
    "    \n",
    "    m = hashlib.sha256()\n",
    "    m.update(id.encode())\n",
    "    return int( m.hexdigest(), 16) % num_buckets\n",
    "    \n",
    "\n",
    "article_table['bucket'] = [get_bucket(pmid, 3) for pmid in article_table['pmid'] ]\n",
    "Counter(article_table['bucket'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 139,
   "id": "b9b9cdea-ddc5-4e6d-a7e4-897988409594",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fitting level 1 model for 'METHODS'\n",
      "Fitting level 1 model for 'RESULTS'\n",
      "Fitting level 1 model for 'DISCUSSION'\n",
      "Fitting level 1 model for 'INTRODUCTION'\n",
      "Fitting level 1 model for 'ABSTRACT'\n"
     ]
    }
   ],
   "source": [
    "train1 = article_table['bucket']==1  # [ 1 if b==1 else 0 for b in article_table['bucket'] ]\n",
    "train2 = article_table['bucket']==2\n",
    "test = article_table['bucket']==0\n",
    "\n",
    "X_all = [v for v in article_table['text_vector'].values ]\n",
    "\n",
    "level1_models = {}\n",
    "for target in targets:\n",
    "    print(f\"Fitting level 1 model for '{target}'\")\n",
    "    train1_idx = np.where(train1==1)[0]\n",
    "    flags = np.array([h==target for h in h1_list])[train1_idx]\n",
    "    clf = LogisticRegressionCV(cv=5, scoring='roc_auc', n_jobs=-1, max_iter=10000)\n",
    "    clf.fit(np.array(X_all)[train1], flags)\n",
    "    level1_models[flag_col] = clf\n",
    "\n",
    "with open('level1_models.pkl', 'wb') as model_fh_out:\n",
    "    pickle.dump(models, model_fh_out)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "id": "70acd29c-4bf2-4d40-914e-24c45d792722",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "id": "3bd5b1df-f2c8-4b55-9286-fba4efd7c98b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "False"
      ]
     },
     "execution_count": 136,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len([v for v in np.where(train1==1)[0]] )\n",
    "\n",
    "train1_idx = np.where(train1==True)[0]\n",
    "len(train1_idx) # 63162\n",
    "\n",
    "# len(np.where(train1==True)[0]) # 63162\n",
    "\n",
    "len(h1_list)  # 195695\n",
    "\n",
    "flags = [h==target for h in h1_list]\n",
    "len(flags) #195695\n",
    "sum(flags) #43958\n",
    "\n",
    "np.array(train1_idx)\n",
    "len(np.array(flags)[np.array(train1_idx)])\n",
    "\n",
    "h1_list == target"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "id": "72f5462e-db78-40b9-973d-f7d644445835",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " 0,\n",
       " ...]"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[ 1 if x else 0 for x in train1 ]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "7f254347-c370-43f2-b445-85aecc9cfa0c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1788.0000000000002"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "# Predict flags from all model scores using a decision tree.\n",
    "\n",
    "pat = 'population'\n",
    "y = pattern_flags[pat]\n",
    "\n",
    "from sklearn import tree\n",
    "dt_clf = tree.DecisionTreeClassifier(max_depth=1)\n",
    "dt_clf = dt_clf.fit(scores_df, y)\n",
    "\n",
    "dt_scores = dt_clf.predict_proba(scores_df)[:,1]\n",
    "\n",
    "np.sum(dt_scores) # for 'abstract' sum=689.0 with any max_depth"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e18e5239-7fb5-41c4-86c7-15513b0a65a4",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
